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Although T cells are the main players in multiple sclerosis (MS) and its animal model experimental autoimmune 
encephalomyelitis (EAE), the role of B cells and their soluble effector molecules (antibodies) is being 
progressively appreciated regarding disease development. Previous observations from our department 
showed that autoantigen-specific B cells contribute substantially to the pathogenesis of CNS autoimmune 
disease through the production of myelin-specific antibodies. These autoantibodies accumulated in CNS-
resident antigen-presenting cells and facilitated the reactivation of invading autoreactive T cells, resulting in 
an earlier manifestation of clinical disease. These results showed that antibodies exert additional mechanisms 
involved in CNS autoimmune disease exacerbation, in contrast to previous studies that focused exclusively on 
the role of antibody-mediated demyelination in EAE exacerbation. It is known that antibody effector 
mechanisms are dependent on the antibody isotype. Therefore, the aim of this study was to modify the 
antibody isotype produced by myelin-specific hybridoma cell lines and to characterize the mechanisms by 
which antibodies of different isotypes exert their pathogenic functions in CNS autoimmunity. Using genetic 
engineering approaches based on the recently characterized CRISPR-Cas9 system, we could produce different 
isotypes from two hybridoma cell lines, which produce antibodies specific for myelin oligodendrocyte 
glycoprotein (MOG), while preserving their antigen specificity. We could demonstrate that antibody disease-
modifying effects were isotype-dependent in the active and transfer EAE model, with all investigated IgGs 
subclasses but no any other antibody isotypes tested being involved in disease acceleration. Furthermore, 
using a T-cell activation reporter (Nur 77-GFP) we found that IgG-treated animals presented higher 
percentages of activated CD4+ T cells in the CNS. Regarding the role of demyelination in EAE, our histological 
analysis indicated that exclusively antibodies of the IgG isotype had demyelinating potential, with IgG2a and 
IgG2b antibodies showing more demyelination compared to IgG1. Moreover, in the absence of Fcγ receptors 
(FcγR I-IV KO mice), the disease acceleration effect was abrogated but, interestingly, the demyelinating 
potential of antibodies of the IgG isotype was increased. Taken these results into consideration, we propose 
that the disease acceleration effect and CNS demyelination are two independent mechanisms driven by 
antibodies. While disease acceleration is dependent on the presence of Fc receptors, demyelination seems to 
be dependent on other molecular cues, such as the complement system. Antibody isotypes have different 
affinities regarding Fc receptor binding and complement fixation and, consequently, there is a preference 
towards one of these systems. However, the preferential effector mechanism triggered by these antibody 






1.1. Multiple sclerosis as a heterogeneous immune-mediated disease 
Multiple sclerosis (MS) is the most common chronic, inflammatory demyelinating disease of the central 
nervous system (CNS)1,2. Among young adults, it represents the main cause of neurologic disability, affecting 
over 2.5 million individuals worldwide. MS pathological hallmarks are classically found in the brain and, in 
some patients, also in the spinal cord. These lesions are the consequence of an autoimmune attack of 
autoreactive immune cells to the myelin sheaths, leading to tissue inflammation, demyelination, axonal 
damage and gliosis3.  
There are two major forms of MS, Relapsing-remitting MS (RRMS) and Primary Progressive MS (PPMS), which 
represent 85-90% and 10-15% of the patients respectively1. RRMS affects about two times more frequently 
women than men, and it is characterized by recurrent episodes of neurologic dysfunction followed by partial 
recovery. Approximately 60% of the RRMS patients develop later in life a secondary progressive (SPMS) 
disease course, which may lead to disease exacerbation associated with neurodegeneration and progressive 
accumulation of disability. PPMS patients, representing the smallest fraction of MS patients, undergo a sudden 
disease onset and constant disease progression. Additionally, a rare variant of PPMS presents acute 
exacerbations with periods of relapse (progressive-relapsing MS)1,3. 
The histopathological alterations among patients, as well as the affected CNS functions and response to 
treatment, can vary significantly, indicating that MS is a highly heterogeneous disease specially at early 
timepoints4. Even though the factors determining this heterogeneity are not completely understood, it is 
probably a consequence of the interplay between both etiological risk factors and pathomechanisms4,5. The 
etiology of MS involves the interaction of environmental factors and several complex genetic traits. 
Environmental factors participating in MS etiology include low vitamin D levels6,7, diet habits such as high salt 
intake and smoking8,9, but also infections such as Epstein-Barr virus5. Concerning the genetic traits promoting 
MS, genome-wide association studies have identified several risk loci, almost all of them related to the 
immune system10. Examples of these loci are variations of the human leukocyte antigen (HLA) and genes 
coding for cytokine pathways. Among the most relevant pathomechanisms involved in MS etiology, 
autoimmune inflammation, de-and remyelination, secondary and primary neurodegeneration with axonal and 
neuronal loss, astrogliosis and metabolic alterations are included1,3,11. All these pathomechanisms interplay in 
diverse manners on different groups of patients, being this interplay probably underlying the different 
phenotypical presentations of MS. 
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Although MS lesions can arise anywhere in the CNS, there is a preferential distribution in the optic nerve, 
spinal cord, brain stem and periventricular areas2. White matter pathology is a common feature of MS lesions, 
but grey matter pathology can arise in areas like cortex, deep grey matter and spinal cord, being commonly 
associated with the chronic phase of the disease1,2. Autopsies and biopsies from patients allowed the definition 
of four lesion patterns based on infiltrating immune cells, deposition of humoral factors, and loss of 
oligodendrocyte and/or myelin proteins. Demyelinating lesions of pattern I and II share similar features, where 
predominantly macrophages, but also T cells, are present surrounding active demyelination plaques close to 
veins and venules. These two patterns are distinguished by the deposition of Igs and complement C9neo 
antigen at the demyelination sites, where C9neo antigen deposition is exclusive to pattern II. Pattern III lesions 
also contain inflammatory infiltrates composed of mainly T cells, but also macrophages and activated microglia. 
The main characteristic of pattern III lesions is the loss of myelin-associated glycoprotein (MAG) and 
oligodendrocyte apoptosis, which can sometimes extend into to the normal appearing white matter. Finally, 
pattern IV lesions are also characterized by presence of large amounts of T cells and macrophages, primary 
oligodendrocyte degeneration and lack of remyelination plaques. 
1.2. Animal models for the study of multiple sclerosis: experimental autoimmune 
encephalomyelitis  
Experimental Autoimmune Encephalomyelitis (EAE) is the most widely used model for the study of MS11. 
Despite not being the only model for the study of MS, EAE has made an important contribution to the 
understanding of MS since its establishment during the 20th century12. Several animal species have been used 
for the induction of EAE, rodents being nowadays the most frequently used ones13, though non-human 
primates are also commonly used, given their close evolutionary relationship with humans11.  
In rodents, EAE can be induced both by active immunization with CNS antigens or by adoptive transfer of 
myelin specific T cells. In the active EAE model, animals are immunized with an emulsion containing complete 
Freund´s adjuvant (CFA), and myelin components with myelin oligodendrocyte glycoprotein (MOG), myelin 
basic protein (MPB), proteolipid protein (PLP) or with its T-cell relevant peptides as the most frequent 
examples. This immunization protocol induces the activation and proliferation of myelin-specific T cells in 
draining lymph nodes, which egress from the lymph nodes to the bloodstream and are able, in a later stage, 
to invade the CNS. T-cells infiltration into the CNS occurs together with other cells of the immune system, such 
as neutrophils, monocytes, macrophages, dendritic cells and NK cells. All these cells together mediate lesion 
formation and demyelination, producing a MS-like clinical course characterized by ascending paralysis and 
weight loss11. In the adoptive transfer EAE model, pre-activated myelin-specific T cells are transferred into 
recipient animals, which develop an ascending paralysis during the following days after T-cell transfer14,15. 
These activated myelin-specific T cells do not require further priming in the lymph nodes to invade the CNS. 
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However, CNS-invading T cells in both the active immunization protocol and the adoptive transfer protocol 
require a further reactivation step at the meninges by local antigen-presenting cells16,17. 
Both EAE and MS are driven by autoimmune processes, even though the animal model does not fully resemble 
all the features of human MS. Furthermore, while in MS animal models the antigen is known, this is not the 
case for MS. However, the development of different EAE models by using different antigens and mouse strains 
allowed the reproduction of different aspects of MS. 
For example, a chronic form of EAE where lesions are predominantly present in the spinal cord but not in the 
brain can be induced upon immunization of C57Bl/6 mice with MOG protein or the T cell epitope MOG35-553,12,13. 
Furthermore, MOG-specific T cell receptor transgenic mice (2D2 mice) develop spontaneous autoimmune 
disease with a very low incidence (4%), whereas double transgenic animals presenting MOG-specific T and B 
cells develop spontaneous disease with an incidence of 58%18. Moreover, the relapsing-remitting course of 
MS can be modelled by immunization of SJL mice with PLP, or by adoptive transfer of PLP139-151 primed T 
cells19,20. Finally, T-cell receptor transgenic mice on the SJL background can spontaneously develop EAE with a 
relapse-remitting disease course21. Nowadays, only few animal models are available that can reproduce the 
brain inflammation observed in MS patients22,23. In this regard, our department recently developed a new 
model in the Lewis rat by adoptive transfer of β-synuclein specific T cells, which resembled several pathological 
hallmarks of MS, including grey matter inflammation and brain atrophy24. 
1.3. B cells participate in MS and EAE pathology 
Although T cells are the main drivers of MS, the role of B cells in disease pathogenesis is becoming 
progressively more acknowledged. The hypothesis of B-cell contribution to MS pathogenesis is supported by 
the presence of oligoclonal bands in the CSF of MS patients25,26, the beneficial effects observed in patients 
undergoing B-cell depleting therapies with monoclonal anti-CD20 antibodies27,28, and the therapeutic outcome 
of plasma exchange29. Furthermore, the deposition of complement and immunoglobulins within the CNS 
parenchyma as well as the presence of tertiary lymphoid organs within the meningeal tissue of MS patients 
supports the crucial role of B cells in MS pathology30,31. In the EAE model, B cells have been reported to have 
disease-modifying effects, both ameliorating and worsening the disease. Knock in C57Bl/6 animals carrying a 
B cell receptor (BCR) with restricted specificity to MOG (Th mice), develop a more severe clinical course after 
immunization with recombinant MOG protein (rmMOG) compared to Wild-type (WT) animals32. In spite of the 
restricted MOG-specific BCR expression in these animals, they do not develop spontaneously neurological 
deficits, but nevertheless, when Th mice are crossed with transgenic animals carrying T cells with restricted 
TCR specificity to MOG (2D2 mice), 58% of the offspring develop spontaneous EAE33. 
5 
 
Extensive research on the EAE model has also identified B cells as important players in CNS inflammation 
through different pathogenic mechanisms. Molnarfi and collaborators showed that antigen presentation 
represents a crucial mechanism for disease promotion, given that selective knock out of MHC II expression on 
B cells led to disease resistance34. Furthermore, B cell depletion therapy also ameliorates EAE disease course, 
presumably by the reduction of pro-inflammatory cytokines such as IL-6, and consequently leading to a general 
reduction of bystander activation of immune cells35, although other studies have pointed at B cells driving anti-
inflammatory effects in EAE through the production of cytokines such as IL-10 or IL-3536,37. Finally, activated 
self-reactive B cells can differentiate into plasma cells, which may produce antibodies recognizing CNS 
structures and therefore exacerbating the damage in CNS lesions38. 
1.4. B cell activation leads to the production of different antibody isotypes through 
Class-switch recombination 
1.4.1. BCR activation triggers antigen loading into MHC-II and exposure at the B cell 
membrane 
Immature B cells are generated in the bone marrow, and they are selected through an assessment of the 
functionality of their BCR39. After selection, these immature B cells migrate to the spleen to undergo their final 
maturation stages, becoming naïve mature B cells. Upon activation, they differentiate into plasmablasts (short 
lived) and plasma cells (long lived), which are antibody-secreting cells (ASC).  
Antigen binding to the BCR triggers B cell activation, where a signalling cascade mediated by cytoplasmic 
immunoreceptor tyrosine activations motifs (ITAMs), and several tyrosine kinases such as Lyn and Syk, 
mediate the internalization of the BCR-antigen complex in a clathrin-dependent manner40. The formed vesicles 
then undergo a series of biochemical changes evolving to a late endosome and, in a later stage, they are 
delivered to peptide-loading compartments, which contain newly synthesized MHC-II molecules plus the 
invariant chain (li) (Figure 1). li contains the Class-II associated invariant chain peptide (CLIP), which prevents 
the binding of self-peptide fragments to MHC-II during this process. The pH of these compartments decreases 
progressively, allowing Ig processing into antigen-binding (Fab) and crystallizable fragment (Fc) and, after a 
cascade of folding and proteolytic events, the antigen becomes available. Processing of li by DM upon acidic 
degradation of DO (which constitutively inhibits DM), allows the peptides to be loaded in MHC-II molecules, 




Figure 1. B cell activation by crosslinking of the BCR with its specific antigen trigger internalization of the BCR-antigen 
complex and antigen loading into MHC-II molecules. A schematic view of the events after BCR activation is depicted. 
Crosslinking of the antigen with the BCR elicits its internalization and processing. Proteolytic cleavage of the Fab and Fc 
Ig fragments makes the antigen available to be loaded in MHC-II molecules. Newly formed MHC-II molecules covered by 
li are processed, conforming the endosomal pH increase, leading finally to free MHC-II molecules that can bind the 
internalized antigen, and be presented at the cell membrane for its recognition by CD4+ T cells. Adapted from Adler et 
al. (2017) Front Immunol. 
 
In the peripheral lymphoid organs, CD4+ T helper cells recognize their cognate antigens presented by activated 
B cells in the context of MHC-II and coordinate their differentiation into antibody-secreting cells41,42. These T 
helper cells express CD40 ligand upon TCR engagement, which binds to CD40 expressed at the surface of B 
cells. Further signals are required to activate B cells, such as interaction of B cell CD80/CD86 with CD28 
expressed by T cells, and release of cytokines by CD4+ T cells such as IL-4, IL-5 and IL-6. Additionally, ligation 
of CD40 to CD40L synergizes with IL-4 to induce the expression of the activation-induced cytidine deaminase 
(AID) protein43,44. All these events together trigger B cell proliferation, somatic hypermutation and Class-switch 
recombination (CSR). Somatic hypermutation generates a high amount of point mutations in the V genes of 
the heavy (H) and light (L) chains, which lead to the generation of high-affinity antibodies against a concrete 
antigen. On the other hand, CSR modifies the immunoglobulin heavy-chain constant region (CH) gene 
expressed from the constant µ region to a different CH genes, resulting in a switch of the immunoglobulin 
isotype from IgM/IgD to IgG, IgE or IgA while preserving antigen specificity42. 
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1.4.2. Class switch recombination is crucial for the maturation of the antibody response 
The immunoglobulin constant H locus consists of an ordered array of constant H genes, which are flanked at 
their 5’ region by a switch (S) region composed of tandemly repetitive unit sequences with several palindromic 
sequences43 (Figure 2). CSR takes place between two S regions located upstream of the constant H of Cµ and 
a different constant domain located downstream of Cδ. The Cµ gene is located downstream of the VH(D)JH 
cassette43,45. Consequently, CSR between Sµ and another SH region located 5’ to a CH gene brings that particular 
CH gene adjacent to the VH(D)JH cassette exon. Three steps drive class-switch recombination: (i) choice of a 
downstream S region as a target to pair in a later stage with the targeted Sµ region, (ii) recognition and 
cleavage of the target DNA by AID, and (iii) repair and ligation of the broken DNA ends by non-homologous 
end joining (NHEJ), resulting in a looped-out deletion. CSR is highly dependent on cell proliferation, which is 
related to the ability of the cell to switch to a different isotype. Two complete rounds of cell division are 
required to switch to IgG and IgA, and probably additional rounds are require for switching to IgE42,43. CSR 
towards a concrete CH domain is dependent on the cytokine production by CD4+ T cells. For example, while 
isotype switching to IgA is highly dependent on TGFβ1, IL-4 dependent activation of STAT6 is required for 






Figure 2. Immunoglobulin isotype class switch is driven by an intrachromosomal deletional recombination event. An 
example of Ig class switch recombination is depicted. Upon ligation of CD40-CD40L, transcription of AID is induced. This 
enzyme deaminates dC resdiues in both sides of transcriptionally active S regions, which flank the constant H sequences 
for different isotypes at their 5’ side, and starting a process that leads to double-strand DNA breaks in both S regions. 
Ligation of both opened S regions by NHEJ repair mechanisms leads to the positioning of a new constant H region adjacent 
to the VH exon. Transcription of this locus lead to production of antibodies of a different isotype. Adapted from Stavnezer 










1.5. All antibody isotypes have a similar molecular structure  
Immunoglobulins belong to the immunoglobulin super-family, which is a large family of cell surface and 
soluble proteins involved in the recognition, binding, or adhesion of cells. Members of this superfamily have 
structural features in common with immunoglobulins.  
Antibodies consist of two heavy and two light chains (Figure 3). The light chains can be further classified as 
either the kappa or the lambda chain based on differences in polypeptide sequence. The antibody structure 
contains two antigen-binding fragments (Fabs) and the crystallisable fragment (Fc), which are linked together 
through a disulphide bridge between two conserved cysteine residues at the heavy chains, and each heavy 
chain is linked to a light chain by a disulfide bond48. In every immunoglobulin molecule, the two heavy and 
light chains are identical, making it possible for antibodies to bind simultaneously two identical structures49. 
While the light chains contains one variable domain and one constant domain, the heavy chains contain one 
variable domain, and either three (IgD, IgG and IgA) or four constant domains (IgM and IgE). A spacer hinge 
region between the first and second constant domains (CH1 and CH2) is normally present in immunoglobulins 
with three C domains. The class, and therefore the effector function of an antibody, is defined by the structure 
of its heavy chain. The five major classes of immunoglobulin are IgM, IgD, IgG, IgA and IgE. These isotypes 
differ in their abundance in plasma, preferential location, half-life and biological functions. IgGs represent the 
most abundant antibody isotype in mouse serum49,50. 
 
Figure 3. Antibody structure consists of two heavy chains and two light chains. Antibody structure of a regular IgG 
molecule is depicted. Two heavy chains (dark blue) are connected to each other by a disulphide bridge. The light chains 
(light blue) are connected to the heavy chains also by disulphide bridges, configuring the Fab region. The two Fab 
fragments are connected to the Fc part through the hinge region, where the link of the two heavy chains occur. At the 




1.6. Antibody isotypes have different properties and biological functions 
1.6.1. IgM  
IgM is the first antibody class produced by B cells during an immune response. IgM can exist as a membrane-
bound monomer or as complex structure, where several IgM monomers form a pentamer51. In both mice and 
in humans, pentameric IgM has a molecular weight of 900 kDa and high affinity to complement, having a 1000-
fold greater binding affinity to C1q compared to IgG. A full IgM pentamer contains three different polypeptides 
types: heavy chains, light chains and J-chain. While the light chains are identical to other isotypes, IgM contain 
four constant heavy domains (CH1-CH4), where the last heavy domain (CH4) associate to the J-chain, allowing 
the binding to other IgM monomers and adopting a pentamer configuration (Figure 4).  
The secreted form of IgM (sIgM) has low affinity for antigens compared to other antibody isotypes, but its 
pentameric structure confers IgM a high valency, and therefore it is highly efficient mediating agglutination 
and elimination of pathogens52. Secretory IgM can be further classified in natural and immune IgM53. Natural 
IgM is a polyreactive immunoglobulin, and it drives phagocytosis of apoptotic cells through C1q binding. On 
the other hand, exposure to pathogens induce the production of immune IgM, which is antigen specific. 
Complement binds to IgM when it recognizes its cognate antigen, eliciting an enhanced humoral response 
where the production of antigen specific IgM is increased by several hundred-fold54. 
Three different types of receptors mediate the effects of IgM: FcµR, polymeric Ig receptor (pIgR) and the 
receptor for both IgA and IgM (Fcα/µR)55,56. pIgR is expressed on the mucous epithelium and ducts of secretory 
glands, at the basolateral membrane of epithelial cells, as well as in the intestine, kidney, pancreas, lung and 
endometrium. This receptor mediates the transport across mucous membranes of sIgA and sIgM through a 
three-stage process, which imply the endocytosis of the complex, several enzymatic-processing steps, and 
finally the release of the immunoglobulin through the apical region of the epithelial cells52. 
Fcα/µR can bind both polymeric IgA and polymeric IgM, having higher affinity for IgM than for IgA in mice. This 
receptor is expressed in all lymphoid tissues, kidney, intestine, lung, liver and myocardium. At the cell level, B 
cells and macrophages express Fcα/µR, but not T-cells, granulocytes and NK cells. Within the intestine, Fcα/µR 
play a role in both local and systemic immune responses, as crosslinking with IgM and IgA on intestinal 
macrophages, plasma cells and Paneth cells evoke the internalization of the receptor, and this process 
presumably leads to antigen presentation52,57.  
FcµR was the last described receptor for IgM. Unlike other Fc receptors, the FcµR does not present ITAM or 
ITIM motifs in its cytoplasmatic domain, but it rather contains serine and tyrosine residues susceptible to 
phosphorylation. This receptor is specific for IgM and does not bind other antibody isotypes, and in mice it is 
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predominantly expressed by B cells, but also by monocytes, macrophages, granulocytes and dendritic cells. 
Despite the function of FcµR is not yet being fully understood, recent research pinpoints to a role in regulating 
the transport and cell-surface expression of IgM-BCR, limiting the amount of complexes that are transported 
to the cell membrane58. 
 
Figure 4. Antibody isotypes have different structures. The structure of the five main antibody isotypes is depicted. While 
IgD, IgE and IgG present a monomeric structure, IgA and IgM can form dimers by the binding of several monomers through 
a J-chain. Light chains are depicted in yellow. Heavy chains are depicted in blue. J-chain of IgA and IgM is indicated with 
a red rectangle and black lines. Adapted from Duarte JH (2016). Nat Immunol 
1.6.2. IgD 
IgD represents the most enigmatic isotype of all antibody isotypes. Its structure resembles that of IgGs, having 
a molecular weight of 180 kDa59. Circulating IgD is found at very low concentrations and its half-life is rather 
short. It is assumed to have homeostatic functions and, although it is not known to participate in all antibody 
effector mechanisms, it is known to enhance antibody responses and to activate the alternative complement 
pathway. Antigen-naïve mature B cells dually express surface IgD and IgM, where differential polyadenylation 
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and alternative splicing processing of the transcript containing both Cµ and Cδ regulate the membrane 
expression of both immunoglobulins. This suggest that both immunoglobulins accomplish distinct functions 
for relevant B cell developmental stages, although IgD is able to replace IgM in IgM KO animals. Furthermore, 
KO animals for IgD develop normal immune responses but a delayed antibody affinity maturation. CD4+ T cells 
express IgD membrane receptors both in human and mice, which bind secreted and membrane-bound IgD 
and are upregulated upon cross-linking with polymeric IgD and downregulated by monomeric IgD59,60. Finally, 
recent research has shown that secreted IgD binds to mast cells and basophils by interacting with the CD44 
binding protein galectine-9, eliciting a Th2 cell-mediated response that enhances the production of antigen-
specific IgG1 and IgE by B cells61. 
1.6.3. IgG 
In humans, four IgG subclasses exist and they are classified according to their serum levels 
(IgG1>IgG2>IgG3>IgG4). In contrast, in mice they are classified as IgG1, IgG2b, IgG2a and IgG3. The heavy chain 
of all these subclasses contain three constant domains, and have a molecular weight of 150 kDa49. They are 
present as monomers at high levels in serum and have a long half-life, where the intracellular neonatal Fc 
receptor (FcRn) plays an important role avoiding the degradation of IgGs at the lysosomal compartment62,63. 
The IgG subclasses have amino acid variations in the Fc domains, as well as distinct hinge regions, which make 
these antibody isotypes perform differently regarding their effector mechanisms. IgG1 has a higher affinity to 
Fc receptors and is known not to bind complement efficiently. On the other hand, IgG2b and IgG2a interact 
efficiently with Fcγ receptors (FcγR) and trigger the activation of the complement cascade with high efficiency. 
IgG3 is also known to bind Fc receptors with low affinity and to bind complement efficiently64,65. IgG subclass 
expression is influenced by the cytokine environment. While Th2 cytokines such as IL-4 induce switching to 
IgG1, Th1 cytokines like IFN-γ lead to the production of IgG2a, IgG2b and IgG365. Among all the IgG subclasses, 
IgG2b and IgG2a are considered to be the most potent IgGs regarding the activation of effector responses, 
which is normally attributed to their higher capacity to fix complement. 
IgGs perform their effector functions through different types of activating and inhibitory FcγRs66. FcγRs can be 
divided in two groups according to their ability to bind the Fc domain of IgGs. Type I FcγRs recognize the Fc 
region in its open conformation, whereas type II FcγRs recognize the Fc region in its closed conformation. Both 
in humans and mice, different type I FcγRs activating receptors and one inhibitory receptor can be found. In 
mice, there are three activating FcγRs (FcγRI, FcγRIII and FcγRIV), which consist of a specific alpha-chain and a 
common γ-chain, which is associated to intracellular immunoreceptor tyrosine-based activation motifs 
(ITAMs). In contrast, the inhibitory receptor FcγRIIb consists of a single alpha chain associated to intracellular 
immunoreceptor tyrosine-based inhibition motifs (ITIMs)67. These receptors are expressed by macrophages, 




The structure of IgE resembles that of IgGs, but IgE contains one further constant domain in its heavy chain at 
the Fc fragment. IgE has a molecular weight of 190 kDa and is the least abundant Ig isotype in plasma, having 
in mice a normal serum concentration of 0-0001-0.001 mg/ml62. The role of IgE in immune responses against 
parasites and within allergic reactions has been extensively documented68. For example, worm infection 
induces a strong Th2 immune response associated with mastocytosis, eosinophilia, antibody class-switching 
to produce IgE and production of IL-4, IL-5 and IL-1369. In allergic reactions, mast cells and basophils release 
their cytoplasmic granules upon cross-linking of the cognate allergen with IgE molecules, which are 
constitutively located at the membrane of these cells70. These granules trigger local inflammation, as they 
contain several inflammatory molecules such as histamine, serine proteases, carboxypeptidase A and 
proteoglycans. 
The Fc receptors that recognize the Fc domain of IgE constitute the Fcε receptor family, and include a high 
affinity and a low affinity receptor, which do not share any structural similarity71,72. The high affinity receptor, 
FcεRI is a heterotetramer composed by one α subunit, one β subunit and a homodimer of the FcγR common 
γ-chain. The FcγR common γ-chain homodimer, together with the β subunit, promote the downstream 
signalling cascade following engagement of IgE. Mast cells and basophils express FcεRI in their membrane, 
which upon crosslinking with IgE mediates degranulation and cytokine release. The low affinity receptor for 
IgE, FcεRII or CD23, belongs to the C-type lectins receptors. FcεRII is formed by trimers that self-associate 
through their extracellular domains forming an alpha-helical coiled-coil structure, where the lectin domains 
hold together at the end of the whole structure. B cells express FcεRII together with the FcγRIIB, with both 
receptors being implied in the regulation of IgE production.  
1.6.5. IgA 
IgA is the second most prevalent antibody found in human serum after IgG, having a normal concentration of 
2-3 mg/ml. The Fc region of IgA monomers consists of three constant domains, and has a molecular weight of 
160 kDa. The half-life of IgA in serum is short, and it is able to fix complement62,73,74. In humans, two isoforms 
of IgA exist (A1 and A2), but in mice just one isoform of IgA exists. This immunoglobulin can be found as a 
monomer or as a dimer when secreted, where a J chain together with disulfide bridges stabilize the dimeric 
structure. IgA production exceeds the production of other antibody isotypes when measured on a daily basis, 
and it plays a key role in immune protection by blocking pathogens from attaching to intestinal epithelial cells. 
This blocking process, known as immune exclusion, is driven by the direct recognition of receptor-binding 
domains from microbial pathogens or toxins, together with a series of events involving agglutination, 
entrapment in mucus and clearance through peristalsis75.  
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Development of intestinal IgA is highly dependent on commensal colonization, since germ-free mice have 
reduced numbers of IgA+ ASC, and it has been shown to facilitate the uptake of antigen across the intestinal 
epithelium, facilitating antigen presentation and priming of adaptive immunity76. Although a Fc receptor for 
IgA exists in humans (the FcαRI which mediates IgA effects77), this is not the case in mice75. In these animals, 
IgA has been proposed to exert their mechanisms through the pIgR, since KO animals for this receptor show 
40 times more IgA serum levels than WT animals. It has also been reported to bind to the Fcα/µR, presumably 
participating in antigen presentation52,78. 
1.7. Autoantibodies exert several effector mechanisms within the CNS 
Although the antigen triggering the immune response in MS has not been identified79,80, presence of 
oligoclonal bands in the CSF as well as therapeutic effects of plasmapheresis indicate a pathogenic role for 
autoantibodies in MS25-28. However, a directly pathogenic antibody specificity has not been identified in MS 
patients. Autoantibodies targeting neurofascin, contactin 2 and even the potassium channels KIR4.1 on 
astrocytes have been reported81. MOG is found on the surface of myelinating oligodendrocytes and external 
layers of myelin sheaths in the CNS, as well as MBP and PLP, being a potential target for autoantibodies82. 
Actually, MOG-specific antibodies were detected in children with MS and acute disseminated 
encephalomyelitis (ADEM)81. In total, it is estimated that 30% of patients with MS produce IgGs that have 
pathogenic potential83. 
In active CNS lesions of MS patients, IgG deposition and complement can be observed along with T cells and 
other infiltrating cells at sites of myelin breakdown30,31. In the EAE model, MOG autoantibodies have been 
shown to have high demyelinating capacity, which is dependent on complement fixation. However, MOG 
autoantibodies alone cannot trigger CNS inflammation, since they are not able to induce disease in naïve 
animals84,38. In addition, administration of MOG autoantibodies at high doses at the EAE onset cause severe 
demyelination and exacerbation of the disease85,86,87.  
Autoantibodies can contribute to disease pathogenesis within the CNS through different mechanisms. CNS 
demyelination can be enhanced by antibody-dependent cell cytotoxicity (ADCC) and activation of the 
complement cascade88,84. These two mechanisms are mediated by the antibodies´ Fc part. In ADCC, the Fc 
region is recognized by immune cells expressing Fc receptors, leading to an inflammatory response in order to 
eliminate the target85. On the other hand, the complement binding region is found in the antibody Fc region89. 
Fixation of complement units in the Fc region triggers complement-dependent cell-mediated cytotoxicity 
(CDCC), where immune cells expressing complement receptors recognize the Fc region and attack the target85. 
One further potential demyelinating mechanism would be the activation of the complement cascade 
triggering the formation of the membrane attack complex (MAC) in the target cell membrane, a process known 
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as complement-dependent cytotoxicity (CDC). Finally, the ability of an antibody to trigger these mechanisms 
is highly dependent on the isotype, since they have different affinities for Fc receptor and complement 
fixation66,84,90. 
1.8. CRISPR-Cas9 as a gene editing tool 
CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR associated protein) is kind of 
equivalent of an adaptive immune system in prokaryotes that uses RNA-guided nucleases to cleave foreign 
nucleic acids such as phages or plasmids91. In recent years, it has been widely used to target the genome of 
eukaryotic cells through codon-optimization of the Cas protein with an appropriate nuclear localization signal. 
The most widely used CRISPR-Cas system is the type II CRISPR-Cas9 system, which consist on a Cas9 nuclease 
coupled with a single guide RNA (sgRNA). The sgRNA is a chimeric RNA derived from the fusion of the crRNA 
and the tracrRNA (Figure 5). The Cas9 and sgRNA complex binds to the DNA target sequence that is 
complementary to the sgRNA, and to a protospacer adjacent motif (PAM) sequence, which is found directly 
after the target sequence and is required for target site recognition. Upon binding, the Cas9 makes double 
strand breaks (DSBs) in the genome and the cell will subsequently initiate DNA repair through NHEJ or 
homology-directed repair, depending on the availability of a DNA template. However, the CRISPR-Cas9 system 
has off-target problems since sequences sharing high homology with the sgRNA can be cleaved or mutated. 
Nevertheless, the CRISPR-Cas9 system allows genome editing through its simple design and high efficiency.  
 
Figure 5. Cas9 requires gRNAs for cleaving the target DNA sequence. A) Cas9 is guided to its target DNA by a crRNA and 
a tracrRNA or B) by a chimeric sgRNA resulting from the fusion, through a linker loop, of the crRNA and tracrRNA. Adapted 





B cells participate in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis 
through different effector mechanisms. Recently, our department started to investigate the time frame and 
mechanisms by which MOG-specific B cells contribute to EAE development87. In this study, MOG-specific T 
cells and B cells were tracked during the course of EAE using intravital two-photon imaging, functional 
characterization and genetic approaches. These experiments demonstrated that the presence of MOG-specific 
B cells accelerated and enhanced the clinical course of EAE, but this effect was mediated by MOG-specific 
autoantibodies rather than other effector mechanisms of B cells. MOG-specific autoantibodies have been 
previously reported to aggravate EAE through demyelination92. However, in the setting used for our study, 
MOG-specific autoantibodies were applied at doses that did not exert additional myelin damage, but most 
likely acted through a different effector mechanism, which was relevant for the initial manifestation of the 
disease. Since both effects have been reported to be antibody-dependent, we hypothesized that the different 
effector mechanisms could be balanced when the accessibility of the antibodies (dosing) and their isotype 
were modified.  
The general objective of this study was to evaluate the relevance of the isotype of the MOG-specific antibodies 
for the development of autoimmunity in the central nervous system using the EAE model. The first aim of this 
study was to generate different isotypes of MOG-specific antibodies produced by two hybridoma cell lines 
while preserving their specificity. These cell lines produce MOG-specific antibodies, but the epitope recognized 
by their antibodies is slightly different. To modify the antibody isotype, a CRISPR-Cas9 approach was designed. 
The generation of modified hybridoma cell lines producing antibodies of different isotypes included the 
characterization of immunoglobulins expressed at the membrane and secreted by the cells, targeting of the 
hybridoma cell lines and selection by cell sorting, establishment and characterization of a pure cell line 
producing exclusively the modified isotype, and large-scale production of purified antibody isotypes. The 
second aim of this study was to address the disease modifying effects of different MOG-specific antibody 
isotypes in the EAE model. First, MOG-specific antibodies of different isotypes were used in the active and 
transfer EAE models to evaluate their capacity to modulate the disease course and T cell reactivation within 
the CNS. Furthermore, since MOG-specific autoantibodies have been reported to exacerbate the disease 
through increased demyelination, the effects of different doses and different isotypes on demyelination as 
well as macrophage and T cell infiltration were investigated. Finally, since recognition of the antibody Fc part 
by immune cells expressing Fc receptors triggers antibody-dependent effector functions, we sought to address 
the role of Fc receptors in antibody effector mechanisms within the CNS using knock out animals for different 
Fc receptors, again applying MOG-specific antibodies of different isotypes.   
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3. Materials and Methods 
3.1. Media and Buffers 
RPMI medium 
Advanced RMPI 1640 Medium (GibcoTM, ThermoFisher) was supplemented with 10% Fetal Bovine Serum, 4 
mM L-glutamine, 1% Gibco® Penicillin/Streptomycin (Penicillin (10000 U/ml) and 0,2% β-mercaptoethanol 
(Roth, 99,9%). 
Eagle´s HEPES (EH) Medium 
133.8g DMEM powder (GibcoTM, ThermoFisher) was diluted in 10L H2O, supplemented with 37g NaHCO3 and 
25 mM HEPES (Life Technologies). 
T cell culture media (TCM) 
1 L EH medium was supplemented with 1% Gibco® Penicillin/Streptomycin, 1% Gibco® Non-essential amino 
acids (MEM NEAA, 100x, Life Technologies), 1% of Sodium pyruvate (Gibco®), 1% L-asparagine (Sigma Aldrich), 
1% L-Glutamine (PAN-Biotech) and 10% FCS. 
LB medium 
25 g of LB-medium (Luria/Miller, Roth®) were diluted in 1 L H2O and supplemented with 100 ng/ml of ampicillin. 
Phosphate Buffered Saline (1xPBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 10 mM NaH2PO4 were added to 1 L H2O. 
FACs Buffer 
PBS was supplemented with 0,5% bovine serum albumin (BSA, Roth) and 2 mM Ethylenediaminetetraacetic 
acid tetrasodium salt hydrate (EDTA, Sigma Aldrich) 
Ammonium – chloride – cotassium (ACK) Lysis Buffer 
0,15 M NH4Cl, 1 mM KHCO3 and 0,1 mM EDTA were diluted in H2O and the pH was adjusted to 7.4 with NaOH 
and HCl. 
 
Gel electrophoresis buffer 
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TRIS/Borate/EDTA buffer was prepared with 10,8 g TRIS, 5,5 g boric acid, and 4 ml 0.5M EDTA, diluted in 1 L 
H2O. 
Transfer buffer 
25 mM TRIS, 1,9 M glycin, 10% SDS were diluted into 1 L H2O. The pH was adjusted to 8.3 
Agarose gels for cloning 
0.6 g Agarose (Roth) in 60 ml H20 and heated up at 100°C for 3 min and 0.0001% ethidium bromide was added 
to the mix. 
PK Buffer for genomic DNA isolation 
0.1 M TRIS HCl and 0.05 EDTA were added to 0.5 ml H2O. 
TBS-T 
TBS was prepared by adding 24 g of TRIS and 88g of NaCl to 1 L H20, the pH was adjusted to 7.6. TBS was 
supplemented with 0.05% tween 20 (Roth). 
PBS-T 
1X PBS was supplemented with 0.05% of Triton-X 100 (Roth). 
TMB 
TMB substrate reagent set (BD) was mixed following manufacturer instructions. 
Ammonium- Chloride- Potassium (ACK) Lysis Buffer 
0.15M NH4Cl, 10mM KHCO3, 0.1mM EDTA .2Na was diluted in H2O and the pH was adjusted to 7.2-7.4 with 
1N HCl. 
3.2. Experimental procedures 
Primer design for cloning of genomic DNA Ig sequences 
For the design of suitable primers for cloning and sequencing of the Igs CH regions, Balb/c reference sequences 
from were extracted from the National Center For Biotechnology (NCBI, USA). Several primers were designed 
to amplify the upstream region of the different isotypes, which contained restriction sites for subsequent 
cloning. The sequences of these primers are indicated in the table 1. 
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Table 1. Designed primers for amplification of the sequence preceding the first IgH constant domain of each isotype 
is depicted. 
Upstream IghG1 forward ggtcgacGGCAAAGACAGGAAGGGACTGTTAG 
Upstream IghG1 reverse cggatccTCAGGGAAATAGCCCTTGACCAGGC 
Upstream IghE forward gggatccATAATGGCTTCCAGTCTGCCACCCAG 
Upstream IghE reverse cgaattcGGGTCATGGAAGCAGTGCCTTTACAGGGC 
Upstream IghG2b forward gggatccCATGGATAGAGACCTAGAAGCAAGA 
Upstream IghG2b reverse cgaattcTAGACTGATGGGGGTGTTGTTTTGG 
 
Genomic DNA extraction and Region of interest PCR amplification  
In order to extract crude genomic DNA (gDNA) from the 8.18c5 and Z2 hybridoma cell lines, a proteinase K-
based protocol was used. Briefly, 1 to 2 million cells were transferred to 1.5 ml Eppendorf tubes. The cells 
were centrifuged for 6 min, at 4°C, 1200 rpm / 301 g and the supernatant was removed. The cell pellet was 
incubated overnight at 55°C with a solution containing 20 µl of proteinase K (200 ng/µl), 10 µl of 10% SDS and 
1 ml of PK-Buffer. After incubation, the gDNA was precipitated with isopropanol and centrifuged for 10 min, 
at 4°C, 4000 rpm / 3345 g. The isopropanol was removed and the gDNA was washed with 70% ethanol, 
centrifuged (5 min, at 4°C, 4000 rpm / 3345 g) and air-dried for 10 min. The pellet was then diluted in 500 µl 
of RNAse free water (Invitrogen), and DNA concentration was measured by Nanodrop. 
Regular PCR amplification of the desired loci was performed in a total volume of 40 µl, consisting on: 2 µM of 
forward primer; 2 µM of reverse primer; 2 µM of gDNA; 20 µl of CloneAmp (CloneTech) and RNAse free water 
up to a final volume of 20 µl. The PCR conditions for amplification of the upstream IgH regions of every isotype 
were: 94°C for 1 min denaturation, 98°C for 30 seconds denaturation, 60°C annealing temperature for 15 
seconds, 72°C extension for 30 seconds. 20 cycles were performed for every DNA fragment. 
DNA extraction and validation 
Amplified DNA was visualized with UV light and extracted using a cutter. After that, pure DNA was extracted 
using GeneJet gel extraction kit (ThermoFisher) following the manufacturer instructions. DNA cut with 






Bacteria and medium 
StellarTM competent cells from TAKARA were used for transformation (30 µl/vector) using SOC medium 
contained within the kit. SOC medium was also prepared following the composition: 2% tryptone, 0.5% yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose. 
Agar plates 
10g Tryptone, 5g yeast extract, 5g NaCl and 15g Agar were diluted in 1 L H2O. The mix was autoclaved (Systec 
VX-150). After, the mix was heated up until 55°C and ampicillin was added (25 ng/ml). 
Cloning into reference vector and sequencing 
Purified DNA was cloned into the cloning vector pJET1.2/blut contained in the CloneJET PCR cloning Kit 
(Thermo Scientific) following manufacturer instructions. Blunted DNA was transformed into Stellar bacteria 
(Takara). Briefly, 30 µl of competent bacteria were incubated with the DNA for 20 minutes at 4°C, followed by 
a heat shock at 42°C for 45 seconds. After that, 1 ml of SOC media was added to the mix, and incubated for 1 
hour at 37°C while shaking. The cell suspension was plated in agar plates containing ampicillin and incubated 
overnight at 37°C. The resulting DNA vector was purified with GeneJet Plasmid Miniprep Kit (Thermo Scientific) 
following the manufacturer instructions. Insert orientation was tested with restriction enzymes. Forward and 
reverse pJET primers (Thermo Scientific) were used for sequencing. Sanger sequencing results were compared 
to the NCBI reference sequence in order to detect polymorphisms. After confirmation of the sequence, several 
guide-RNAs were designed for cloning into DNA vectors containing the sequence for the Cas9 protein (Table 
4). 
Cloning of protospacers into Cas-9-expressing vectors 
10 µM Forward and reverse oligonucleotides were mixed together, and annealing  and phosphorylation was 
performed according to the following protocol: denaturation at 95°C for 5 min, 25°C for 1 min, ramping 
program (0.1°C/s) until 12°C. Cloning of these oligonucleotides into the Cas9-expressing vectors was 
performed following Zhang´s Lab protocols91. 
Cherry recombinant cleavage assay 
The sequences used for protospacers design were extracted from pJET vectors, and introduced by enzyme-
restricted based cloning into CAG-Cherry vectors. This vector contains restriction sites between two homology 
arms that were used for cloning of the target sequence. Further information about this assay is provided in 
the chapter 4.1.3. and Figure 9. 1x105 HEK 293T cells were transfected with 10 µg of CAG-Cherry vectors and 
10 µg of Cas-9 vectors cloned with the protospacers for the target sequence, or empty Cas-9 vectors. The DNA 
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constructs were introduced into the HEK 293T cells using Lipofectamine 2000 (Thermo Scientific), following 
the manufacturer instructions. 48 hours the cells were evaluated by fluorescence microscopy with a Zeiss 
microscope, and the mean fluorescence intensity (MFI) was measured by FACs (FACs Calibur). 
Introduction of DNA constructs into 8.18c5 and Z2 hybridoma cell lines 
10 µg of DNA were introduced into 1x105 8.18c5 or Z2 hybridoma cells by electroporation (Bio-Rad GenePulser 
XcellTM). The cells were diluted in 800 µl of sterile PBS and received a pulse of 625V following an exponential 
protocol (Impedance 50 µF, resistance infinite and 4 mm cuvette size). Electroporated cells were then washed 
with sterile PBS and transferred to 6 well-plates containing RPMI medium. 
Hybridoma culture and production of monoclonal alpha MOG antibodies 
The monoclonal α-MOG antibodies were derived from the 8.18c5 and Z2 hybridomas cell lines. The cell lines 
were expanded in RPMI medium until the cell density reached a concentration of 1400 cells/cm2 or 2.528 
cells/cm2. Once the appropriate cell density was reached, the culture medium was exchanged to PFHM-II 
(Thermo Fisher) and cells were kept in culture for 14 days. After this time, cell culture supernatants were 
harvested, centrifuged at 880 rpm / 162 g for 8 minutes and filtered through 0.2 µm filters (Sarsted, INC.). 
Protein purification of IgG antibody isotypes (IgG1, IgG2a and IgG2b) was carried out using 1 ml HiTrap Protein 
G High Performance Columns (GE Healthcare) following the manufacturer instructions. IgE and IgA antibody 
isotypes were purified using 1 ml HiTrap Protein L High Performance Columns (GE Healthcare) following the 
manufacturer instructions. The eluted fractions were desalted using PD-10 Desalting columns (GE Healthcare) 
following the manufacturer instructions. The proteins were eluted in PBS and quantified using Nanodrop 
(Peqlab). The IgG1 (Ultra Leaf MOPC-21, BioXCell), IgG2a (Ultra Leaf MOPC-173), IgG2b (Ultra Leaf 27-35), IgE 
( Ultra Leaf MEA-36) isotype control were purchased.  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE93 assays were performed using two different polyacrylamide gels at two different Polyacrylamide 
concentrations. For the running gel, 1,33 ml 30% Acrylamide mix were diluted into 2,42 ml H2O. 1,22 ml of 
1,5M Tris-SDS buffer (pH 8,8) was added to the mix, vortexed, and polymerization was achieved by adding 50 
µl of ammonium persulfate (APS) and 20 µl of TEMED. For the stacking gel, 0,22 ml 30% Acrylamide mix were 
diluted into 1.02 ml of H2O. 0.44 ml 1.5M Tris-SDS buffer (pH 6.6) were then added to the mix, plus 50 µl of 





Gel electrophoresis and Western Blot 
Molecular weight and isotype of the purified monoclonal antibodies was confirmed by gel electrophoresis. 
Briefly, 1 µg of protein was denatured in a β-mercaptoethanol-containing buffer. The denatured protein was 
then loaded into a SDS-PAGE, together with a molecular weight marker (PAGE ruler Prestained plus, Thermo 
scientific). The SDS-PAGE was then transferred into a BIO-RAD electrophoresis cassette and run for 90 min at 
120 V.  
For the molecular weight characterization, the SDS-PAGE gels were stained with Cromassie blue for 5 min and 
washed overnight with water. For the Western Blot94 characterization of the isotype, the SDS-PAGE was 
transferred to a transfer cassette together with a nitrocellulose membrane, and over- and under-laid with 
filter paper and sponges. Protein transfer to the nitrocellulose membrane was performed at 100 V for 1 hour 
at 4°C. After that, the nitrocellulose membrane was washed with H2O, and blocked for 90 min with TBST-BSA 
5%. Following blocking the membrane was transferred to a TBST and BSA (TBST-BSA 5%) solution containing 
the primary antibody (biotin anti-Ig, 1:40000 dilution), and incubated overnight at 4°C. The next day the 
membrane was washed with TBST at room temperature, and transferred to a TBST-BSA 5% solution containing 
the secondary antibody (Streptatividin-APC, 1:8000 dilution), and incubated for 2 hours at room temperature. 
Both Cromassie blue stained gels and immunostained nitrocellulose membranes were then scanned in a GE 
Amershamer Imager 600 scanner (GE Healthcare). 
Hybridoma supernatant ELISA 
Determination of the antibody isotype was achieved by ELISA. In brief, ELISA plates were coated with 4 µg/ml 
recombinant MOG (rMOG) in PBS and incubated overnight at 4°C. Plates were washed with PBS plus 0.05% of 
Tween20 (Roth) (PBS-T), and blocked with PBS plus 5% BSA for 1 hour. After blocking, the plates were washed 
and incubated for two hours with hybridoma culture supernatants at room temperature. Following probe 
incubation, the plates were washed, and incubated for 90 min with biotin-conjugated anti-Ig antibodies in a 
concentration of 1 µg/ml, and ST-HRP antibodies in a 2 µg/ml. Finally, after a further washing step, HRP 
enzymatic reaction with its substrate 3,3´, 5,5´tetramethyilbenzidine (TMB) was induced by incubation for 30 
min of 100 µl of TMB per well, and stopped by addition of 50 µl 1M H2SO4. Absorbance was then measured at 
450 nm with correction wavelength of 620 nm in a SunriseTM ELISA plate reader (Tecan Life Sciencies). 
Flow cytometry 
Isolated cells from tissues were stained with monoclonal antibodies conjugated with fluorochromes. 
Hybridoma cells were stained with both monoclonal antibodies conjugated with fluorochromes, and with 
biotin-conjugated anti-Ig antibodies plus ST-APC antibodies. Cells were stained in 100µl FACs buffer for 15 min 
at 4°C. This process was repeated for second antibody staining. After that the cells were washed with 2 ml 
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FACs buffer and resuspended in EH+EDTA or RPMI medium. A further staining step with ST-APC antibodies 
was performed when hybridoma cells were stained.  
For the assays with T-mMOG cells for testing specificity and isotype of the new purified antibodies derived 
from 8.18c5 and Z2 this protocol was followed, but with a previous incubating the 8.18c5 and Z2 purified 
antibodies for 15 min at 4°C. 
For cell sorting, The BD FACs Aria II Cell Sorter was used and the sorted cells were collected in EH+10% FCS. 
For quantification, 100 µl of PBS containing fluorescent beads were added to the cell suspension at the same 
volume. Quantification measurement were repeated three times using the BD FACs Calibur Cell Analyzer. 
Results obtained with both protocols were analysed with FlowJo software (Tree Star, Inc., USA). The antibodies 
used in this work are specified in Table 2: 
Table 2. All antibodies used for FACs staining are depicted.  
Specificity Clone Label Company 
CD45.2 104 PE BioLegend 
CD4 H129.19 PE-Cy5 BioLegend 
CD3 17A2 APC BioLegend 
IgG1, Isotype ctrl RTK2071 PE BioLegend 
PE-IgG1 RMG1-1 PE BioLegend 
Biotin-IgG1 RMG1-1 Biotin BioLegend 
Biotin-IgG2b RMG2b-1 Biotin BioLegend 
Biotin-IgG2a RMG2a-62 Biotin BioLegend 
Biotin-IgE RME-1 Biotin BioLegend 
Biotin-IgA RMA-1 Biotin BioLegend 
Streptavidin APC X APC BioLegend 
 
RNA isolation, cDNA synthesis and quantitative real-time PCR (qRT-PCR) 
Sorted cells were spun down for 6 min at 4°C, 4000 rpm/ 3345 g in a Centrifuge 5415 R (Eppendorf). The 
supernatant was discarded and the cells were resuspended in 350 µl of QIazol® Lysis Reagent (Qiagen Sciences). 
70 µl of chloroform were added to the suspension, and after 20 min incubation at room temperature, the 
samples were centrifuged for 15 min at 4°C, 12000g. The aqueous phase was then transferred to a different 
tube and RNA precipitation was achieved by addition of 175 µl of isopropanol. 1 µl of glycogen was added to 
the samples and they were incubated overnight at -20°C. The next day, the samples were incubated for 10 
min at room temperature, and centrifuged at 12000g for 10 min at 4°C. Supernatant was discarded, the RNA 
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pellet was washed with 350 µl of 75% ethanol and the samples were centrifuged for 10 min, at 4°C, 12000g. 
Finally, the pellet was air dried for 10 to 15 min at room temperature, and resuspended in 12 µl of UltrapureTM 
Distilled DNAse/RNAse free Water (Invitrogen). 
The RevertAid First Strand cDNA Synthesis kit (Thermo Scientific) was used for retroconversion to cDNA 
following the manufacter´s protocol. The qRT-PCR StepOnePlus™ Real-Time PCR System (Applied Biosystems) 
was used for the qRT-PCR assays. The cDNA-converted samples were then mixed with a qPCR Master Mix 
(Eurogentec) and target-specific TaqMan® probes labelled with FAMTM (6-carboxyfluorescein) and quenched 
by TAMRATM (6-carboxytetramethylrhodamine). Results were analysed with the StepOne-Plus software v2.0. 
Expression of IFNγ, IL-17 and GM-CSF was normalized to HPRT. qPCR primers are listed in Table 3. 
Table 3. List of all primers used for qRT-PCR. 
HPRT Fw (5`-3`) TGCTCGAGATGTCATGAAGG 
Rev (5`-3`) TATGTCCCCCGTTGACTGAT 
Probe [6FAM]ATCACATTGTGGCCCTCTGT[TAM] 
IFNγ Fw (5`-3`) TCAAGTGGCATAGATGTGGAAGAA 
Rev (5`-3`) TGGCTCTGCAGGATTTTCATG 
Probe [6FAM]TCACCATCCTTTTGCCAGTTCCTCCAG [TAM] 
IL-17A Fw (5`-3`) ACTTTCAGGGTCGAGAAGATGCT 
Rev (5`-3`) TTCTGAATCTGCCTCTGAATCCAC 
Probe [6FAM]TGGGTGTGGGCTGCACCTGC [TAM] 
GM-CSF Fw(5`-3`) GGGCGCCTTGAACATGAC 
Rev(5`-3`) CGCATAGGTGGTAACTTGTGTTTC 
Probe [6FAM]CCCCCCAACTCCGGAAACGGA [TAM] 
 
Animals 
All animal experiments were approved by the Lower Saxony state authority LAVES (Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit). Mice breeding was carried out in the 
University Medical Center Göttingen (UMG) under specific pathogen-free conditions. For the in vivo studies, 
different mouse lines (all on the C57Bl/6J genetic background) were used: Wildtype, FcγR+IIB KO95 (crossing 
of FceRg KO96 and FcγRIIB), FcRn KO97, FcγRI+III KO (crossing of FcγRI KO98 and FcγRIII KO99), FcγR I-IV KO 
(crossing of FcγRI KO, FcγRIIB KO, FcγRIII and FcγRIV KO100) and Nur77-GFP101. FcγR KO, FcγR+IIB KO and 
FcγRI+III KO animals were kindly provided by F. Nimmerjahn, University of Erlangen-Nürnberg, Germany. FcγR 
I-IV KO animals were kindly provided by J.S. Verbeek, Leiden University Medical center, The Netherlands. 
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EAE Direct immunization 
10 to 12 weeks old mice were intraperitoneally anesthetized using ketamine (80 mg/kg, Medistar) plus xylazine 
(8 mg/kg, Riemser Arzneimittel) in 0,9% NaCl (Braun). Mice were subcutaneously immunized at the tail basis 
with 25 µg (suboptimal immunization) or 50 µg (optimal immunization) of MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK, purchased from Charité, Institute for Medical Immunology, Berlin) in PBS, 
emulsified in an equal volume of Complete Freund´s adjuvant (CFA) containing Mycobacterium tuberculosis 
H37RA (Difco) at a final concentration of 1 mg/ml.  
Mice were treated with 2 consecutive i.p. injections of Pertussis Toxin (PTX, List Biological Laboratories; 400 
ng/mouse in total), one immediately after immunization and 2 days post immunization.  
Transfer EAE 
Mice were immunized following the previously specified protocol with 75 µg MOG35-55 peptide per animal. 
Shortly before disease onset (days 10 to 12 post immunization), animals were sacrificed by CO2 inhalation and 
draining lymph nodes were extracted. Lymph nodes were then pressed through 70 µm metal strainers to 
obtain single cell suspensions. After quantifying the number of cells, the cell suspensions were diluted in 
mouse T cell culture medium to a final concentration of 5*106 cells/ml and supplemented with 25 µg/ml 
MOG35-55, 25 ng/ml recombinant  mouse IL-12 (R&D) and 20 µg/ml of α-IFNγ Ab (BioXcell, clone XMG1.2) for 
re-stimulation. Cell suspensions were plated in 96-well round bottom plates (100 µl/well, NunclonTM Delta 
Surface, Thermoscientific) and cultured at 37 °C, 5% CO2. 2 days later, the cells were transferred to 96-well flat 
bottom plates (NunclonTM Delta Surface, Thermoscientific) and 24 hours later were harvested. After washing, 
the cell suspensions were diluted in EH medium to a final concentration of 2.5x106 cells and i.p. injected into 
recipient animals.  
EAE assessment 
Animals were daily examined from d8 post immunization or on d2 post T-cell transfer until the end of the 
experiment for clinical signs of disease on a scale from 0 to 10 depending on severity. Clinical scores were 
assigned according to the following criteria: 0, healthy; 1, reduced tone of tail; 2, limp tail, impaired righting; 
3, absent righting; 4, gait ataxia; 5, mild paraparesis of hindlimbs; 6, moderate paraparesis; 7, severe 
paraparesis; 8, tetraparesis; 9, moribund; 10, death. Animals achieving score 7 or higher were sacrificed due 





Isolation of immune cells from the CNS 
Mice were sacrificed by CO2 inhalation and spinal cord was extracted. Spinal cord parenchyma and meninges 
were separated and kept in cold EH medium plus 2 mM EDTA (EH+EDTA). Tissues were subsequently pressed 
through a 70 µM metal strainer in order to obtain a single cell suspension. 90% PercollTM (GE Healthcare) was 
added to the cell suspension, mixed by inversion of the tube and centrifuged (30 min, 2780 rpm / 1615 g, 4°C, 
w/o acceleration or break, Multifuge 1S-R, Heraeus). Finally, the cells were resuspended in FACs Buffer and 
filtered through 40 µm filters before staining. 
Isolation of lymphocytes from the blood 
Mice were sacrificed by CO2 inhalation and blood was extracted by heart puncture using 100 µl 80mM EDTA-
coated syringes. Blood samples were then diluted to a final volume of 1 ml with PBS and carefully pipetted on 
top of Lymphocyte separation medium (LSM 1077, GE Healthcare). After centrifugation (30 min, 2000 rpm / 
836 g, RT, w/o acceleration or break, Multifuge 1S-R, Heraeus) the interphase was collected and washed with 
cold PBS. Erythrocytes lysis was performed by incubation of the cell suspension with ACK lysis buffer for 1 min 
on ice, and after that cells were spun down (1200 rpm / 301 g, 6 min 4°C, Multifuge 1S-R, Heraeus) and 
resuspended in FACs Buffer. 
Histology 
For the histology experiments, animals were transcardially perfused at the specified time points with PBS for 
10 min at 4°C, and 10 min with 4% PFA at 4°C. Spinal cord samples were kept in PFA for 5 days, and after that 
they were dehydrated and included in paraffin. 3 µm thick sections were cut with a LEICA SR 2000R microtome 
and visualized in a Zeiss Axioskop 40 microscope.  
Luxol Fast Blue 
Luxol fast blue (LFB) staining was performed according to the original protocol with some modifications102. In 
brief, after dehydration, the samples were incubated at 56°C in a 0,1% LFB solution. After that, the slides were 
washed with 96% ethanol and H2O. Excess of LFB was removed with 0.1% Li2CO3 for 30s, followed by washing 
in 70% ethanol and H2O. After that, the slides were incubated during 10 min in 0.8% Periodic Acid, washed in 
H2O, and further incubated in Schiff's reagent for 20 additional minutes. The excess of which was washed away 
with a sulphite wash. Finally, the cuts were washed 10 min in tap water, dehydrated and mounted. Analysis 
of percentage of demyelination was performed in ImageJ v1.8. Spinal cord white matter area was calculated 
by subtracting the grey matter area to the total area. Summation of the demyelinating lesions was then used 





For antigen retrieval, the slides were then boiled in citrate buffer for 15  min,  washed  with  PBS,  and  
endogenous  peroxidase  activity  was  blocked with  3%  H2O2 for 15 min at 4ᵒC.  Biotinylated anti-mouse MAC-
3 and CD3 antibodies (1:200, BD biosciences), which were incubated overnight at 4°C. Secondary streptavidin-
HRP antibodies (1:200, DB biosciences) were incubated for 4 hours at room temperature. the peroxidase-
based ABC detection system (DakoCytomation) in combination with diaminobenzidine was used for 
visualization, and all sections were counterstained with hematoxylin. Quantification of MAC-3 stainings was 
performed in imageJ v1.8. In brief, total spinal cord area was calculated and colour deconvolution was applied 
to the image (pre-set: H DAB). The brown channel was selected, light background was removed and threshold 
was established based on the staining intensity. Area occupied by the staining was then related to the total 
area, obtaining the percentage of area occupied by the staining. CD3+ T cells were quantified in imageJ v1.8 
and number of cells per mm2 was calculated considering the total area of the section.  
Statistics 
Animals were randomly assigned to the different 8.18c5, Z2 or isotype control groups. Statistical analysis was 
performed using GraphPad Prism 8. T test was used for analysis of EAE day of onset. One-way Anova plus 
Sidak´s multiple comparison test was done for the analysis of the Nur-77 GFP experiments, for histological 
analysis (LFB, MAC3 and CD3) and for cytokine expression of ex vivo sorted T cells. 
All data is depicted as Mean+/- SEM (standard error of the mean). P-values of statistical differences correspond 
to: 
P ≥ 0,05 ns 
P = 0,01 to 0,05 * 
P = 0,001 to 0,01 ** 
P = 0,0001 to 0,001 *** 
P < 0,0001 **** 







4.1. CRISPR-Cas9-driven isotype switch enables the generation of MOG-specific 
antibodies with different isotypes while preserving antigen specificity 
4.1.1. 8.18c5 hybridoma cells produce exclusively MOG-specific IgG1 antibodies 
Recent studies have pointed to a disease-modulatory role of MOG-specific antibodies in the CNS draining 
lymph nodes, where these autoantibodies triggered activation and expansion of MOG-specific T cells in an Fc-
dependent manner86. In a complementary and parallel study, previous results from our department indicated 
that MOG-specific antibodies exert disease-modifying effects in EAE such as acceleration of disease onset and 
a more severe clinical course of the disease, within the CNS rather than in the periphery87. Both studies made 
use of murine monoclonal MOG-specific antibodies derived from the 8.18c5 hybridoma, which produce IgG1 
antibodies, using the γ1 heavy chain locus.84. Upon transcription, two different IgG1 mRNA transcripts can be 
generated in an alternative splicing-dependent manner (Figure 6A). mRNA transcripts containing the M1 and 
M2 exons will be translated and transported to the cell membrane, being part of the BCR complex, and 
enabling its detection by FACS. Fluorescent staining for IgG1, and all isotypes localized downstream of IgG1, 
revealed that the 8.18c5 hybridoma exclusively express IgG1 antibodies at the membrane level (Figure 6B). 
Alternative splicing-driven excision of the M1 and M2 exons generates mRNA transcripts that, after translation 
in the endoplasmic reticulum, are packed in vesicles and secreted to the extracellular media. To further 
substantiate that the antibodies secreted by the 8.18c5 hybridoma are exclusively of the IgG1 isotype, we 
established a thymoma cell line expressing tomato-labelled mouse MOG at the cell surface (T-mMOG). FACS 
staining of T-mMOG cells with affinity chromatography-purified antibodies from 8.18c5 hybridoma cells 
confirmed the presence of exclusively IgG1 antibodies in the purified fractions (Figure 6C). Furthermore, ELISA 
analysis of 8.18c5 cell culture supernatants indicated that only IgG1 antibodies, but no other isotypes localized 




Figure 6. 8.18c5 hybridoma expresses at the membrane and releases in the supernatant antibodies of the IgG1 isotype: 
A) Schematic overview of the genomic organization of 8.18c5 heavy chain locus (upper), that upon transcription 
generates either a transcript containing membrane bounding signaling peptides (down left), or a transcript lacking these 
signaling peptides that leads to vesicle packaged antibodies that will be secreted (down right). B) 1x106 8.18c5 cells were 
labelled with antibodies recognizing IgG1 and antibody isotypes localized downstream IgG1, or isotype control. C) FACs 
staining of T-mMOG cells with 8.18c5 purified antibodies. Gating strategy is showed in the upper panel. 1x106 8.18c5 cells 
were stained with 0.5 µg of 8.18c5, and PE-conjugated IgG1 or IgG1 isotype control (lower panel). D) ELISA detection of 
8.18c5 antibodies in supernatant. 8.18c5 purified antibodies were tested with recombinant mMOG ELISA-coated plates 





4.1.2. Design and cloning strategy of a CRISPR-Cas9 based approach for the induction of 
antibody isotype switch in the 8.18c5 hybridoma cell line 
Since post-translational processing of immunoglobulins such as the glycosylation pattern have a crucial role in 
antibody effector functions103, we aimed to induce the expression of different heavy chains directly into the 
8.18c5 hybridoma. CRISPR-Cas9 based approaches demonstrated recently to be useful inducing antibody 
isotype switch in hybridoma cell lines45. Considering this, we designed a CRISPR-Cas9 based targeting system 
following the strategy of these previous studies. Cas9-containing specific gRNAs for targeting the upstream 
region of the first constant domain exon of the actually expressed immunoglobulin (IgG1), and upstream of 
the first constant domain exon of the following immunoglobulin to be expressed (IgG2b, IgG2a, IgE or IgA), 
would induce a genomic DNA (gDNA) double-strand break (DSB) (Figure 7). Similar to the natural CSR 
recombination process, the gDNA sequence found between the targeted regions would be deleted, and the 
Cas9-targeted regions would then be re-ligated. Consequently, the new heavy chain constant domains will be 
located directly after the genomic region spanning the already recombined VDJ region. Upon transcription of 
the locus, the transcripts will contain the sequence for the newly recombined isotype.  
 
Figure 7. Emulation of CSR through CRISPR-Cas9-based strategies: Schematic overview of the CRISPR-Cas9 rational 
design followed in order to generate antibody isotypes localized downstream IgG1 while preserving the same antibody 
specificity. Generation of IgE as an example is depicted. CRISPR-Cas9 targeting of both regions inmediately located 
upstream IgG1 and IgE (blue dots) should lead to DSB, excluding the gDNA region located in between and leading to a re-
joining of the DNA strands. In this new configuration, IgE-codifying exons will be located directly downstream the VDJ 
exons, therefore altering the expressed isotype but keeping the antibody specificty intact. 
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Generation of MOG-specific 8.18c5 IgE from IgG1-expressing 8.18c5 cells will be used as an example of the 
protocol used for the generation of different antibody isotypes. Using NCBI reference gDNA sequences from 
Balb/c mice, we designed primers in order to amplify a 500 bp gDNA fragment containing the regions 
preceding the CH1 sequences of IgG1 and IgE (Figure 8A). After cloning and sequencing of the PCR-amplified 
DNA fragments, different guide RNAs (gRNAs) were designed considering the existing protospacer adjacent 
motif (PAM) sequences within the DNA fragments (Figure 8B, top). Table 4 summarizes the sequences of the 
protospacers for CRISPR-Cas9-targeting upstream the IgH constant sequence of different isotypes. The 
selected protospacers were cloned into DNA vectors containing a puromycin resistant cassette for selection 
and the Cas9 protein sequence (Figure 8B, bottom).  
Of note, in order to ensure independent transcription of the different gRNAs within the targeted cells, the 
protospacers for the upstream region of IgG1 were cloned under the U6 promoter, and the protospacers for 
the upstream region of other isotypes were cloned under the H1 promoter. After cloning, the resulting vectors 
were tested with restriction enzymes, and sequenced by Sanger sequencing (Figure 8C). Sequencing data 




Figure 8. Cloning strategy for the generation of 8.18c5 IgE. A) PCR amplification of the gDNA containing the upstream 
regions preceding IgH of IgG1 and IgE. Sequences from NCBI databank were used for primer design. 25 nucleotides-long 
primers carrying restriction enzymes sites were used for PCR amplification. Subsequent gDNA fragments were cloned 
into the cloning vector pJET 1.2/blunt (ThermoFisher) and sequenced by Sanger Sequencing. B) Design of oligonucleotides 
for protospacer cloning into Cas9-containing vectors. 20 nucleotides-long oligonucleotides adjacent to GXX sequences 
(PAM regions) were designed, annealed and phosphorylated, and cloned into cloning vectors containing Cas9 under 
either the U6 or the H1 promoter. C) Cloning was confirmed using BamHI and HindIII restrictions sites and gel 







Table 4. Protospacer sequences for upstream targeting of the IgH regions. Sequences of the protospacers used for 
CRISPR-Cas9 targeting of the 8.18c5 and Z2 hybridoma cell lines are indicated. 
Protospacer sequences for Cas9 targeting upstream gDNA sequences of antibody heavy chain locus 
IgG1 IgG2b 
Ps1  Ps1  
Forward caccGCCTCAGGTCTCATCTGGTC Forward tcccCACAGTGCAAGCTCTGGAGG 
Reverse aaacGACCAGATGAGACCTGAGGC Reverse aaacCCTCCAGAGCTTGCACTGTG 
Ps2  Ps2  
Forward caccGAGGTATAAGAAGTTTAACAG Forward tcccGGTCACAGTGCAAGCTCTGG 
Reverse aaacCTGTTAAACtTCTTATACCTC Reverse aaacCCAGAGCTTGCACTGTGACC 
Ps3    
Forward caccGAGAGTCGGGGACATGGGAA   
Reverse aaacTTCCCATGTCCCCGACTCTC   
IgE IgA 
Ps1  Ps1  
Forward tcccGAATAAAGACAAGACCCAGA Forward tcccGTCGGAGCTGACCAACAGTTC 
Reverse aaacTCTGGGTCTTGTCTTTATTC Reverse aaacGAACTGTTGGTCAGCTCCGA 
Ps2  Ps2  
Forward tcccGGGCAGCTGTGACAGGAGCA Forward tcccgCTGCATTGTGTACCCGCAGT 
Reverse aaacTGCTCCTGTCACAGCTGCC Reverse aaacACTGCGGGTACACAATGCAGc 
 
4.1.3. High cleavage efficiency of the target sequence is achieved with specific guide RNAs 
After introduction of the protospacers in the Cas9 vectors, we tested these DNA construct for cleavage of the 
target sequences using a truncated-Cherry reporter assay (Figure 9A). The target sequences for each gRNA 
were cloned in the middle of a Cherry sequence, which is expressed under a CAG promoter (Figure 9A, middle 
and bottom). In this configuration, the presence of the target DNA sequence impairs Cherry expression, 
limiting its fluorescent emission. Upon cleavage of the target sequence by Cas9, the homology regions of 
Cherry will be able to recombine and lead to a translated functional Cherry protein. Therefore, the increase of 
Cherry fluorescent signal will provide insights into the cleavage efficiency of the target sequence by the 
designed guide-RNAs. HEK cells were transfected with CAG-Cherry DNA vectors containing the target 
sequences for IgG1 and IgE, and Cas9 DNA vectors expressing guide-RNAs for IgG1, IgE or no gRNAs (zero). 
Fluorescently labelled HEK cells were visible 24 hours after lipofectamine transfection (Figure 9B). The 
enhancement of Cherry fluorescence was assessed by FACs 48 hours after lipofectamine transfection (Figure 
9C). Measurement of the Cherry mean fluorescence intensity (MFI) in transfected HEK cells showed that, in 
comparison to the vectors containing no guide-RNAs, Cas9 vectors expressing specific gRNAs for the target 
sequence enhanced the Cherry MFI for both IgG1 and IgE. These results indicate that our Cas9-gRNAs system 
is able to cleave the target sequence. The protospacer sequences indicated in Table 4 were cloned into Cas9 
vectors, and their efficiency was tested using an identical approach. Guide-RNAs showing high cleaving 






Figure 9. Confirmation of Cas9 cleavage efficiency with a split-cherry recombinant assay. A) Schematic overview of the 
Recombinant Cherry Assay (RCA). Upon transcription of the construct, functional gRNAs and Cas9 will cleave their target 
sequences, allowing the recombination of the two homologous cherry regions and leading to an enhancement of Cherry 
fluorescence. B) 105 HEK cells were transfected using a lipofectamine-based approach with 6 µg of DNA containing Cas9 
and protospacers for targeting the upstream region of IgG1 and IgE. Cherry intensity was evaluated by fluorescence 
microscopy (left; Scale bar, 200 µm). C) Cherry MFI was analysed by FACs. Representative MFI counts of Cherry intensity 
for protospacer targeting the upstream region of IgG1 (red) and IgE (green) (right). MFI quantification of Cherry intensity 
upon transfection of protospacers for IgG1, IgE or control Cas9 vectors (bottom). 
4.1.4. CRISPR-Cas9 targeting upstream the IgH constant regions of IgG1 and IgE lead to 
isotype switch in the 8.18c5 hybridoma 
The DNA constructs containing the protospacers for targeting the sequences preceding IgH constant domains 
of IgG1 and IgE were introduced into the 8.18c5 hybridoma cell line by electroporation. After one day, the 
transfected 8.18c5 cells still expressed IgG1 in the membrane but not IgE (Figure 10A left). After 4 days we 
were able to detect two different populations which expressed either IgG1 or IgE at the cell membrane (Figure 
10A middle). We isolated single positive IgE-expressing cells by cell-sorting, and Ig membrane expression was 
further evaluated 3 days later by FACs, which revealed the expression of only IgE at the cell membrane but 
not IgG1 (Figure 10A right), or any other isotype located downstream IgG1 in addition (Figure 10B). Using the 
same protocol but with Cas9 vectors containing the protospacer 1 for the upstream region of IgG2b heavy 
chain instead (Table 4), we could additionally isolate a population expressing exclusively IgG2b at the cell 




Figure 10. CRISPR-Cas9 induced isotype switching of 8.18c5 leads to the expression of a different antibody isotype at 
the membrane level. A) 2x105 8.18c5 cells were electroporated with Cas9-containing DNA vectors and protospacers for 
the upstream region of IgG1 and a different isotype located downstream. An example for the generation of IgE is depicted 
(upper). Transfected cells were analysed during the following days after electroporation and single-positive cells for IgE 
were sorted after 4 days. Stable expression of IgE at the membrane level was confirmed 3 days later (lower). B) FACs 
analysis of IgE positive cells for immunoglobulin membrane expression. 1x106 cells were stained with biotin-conjugated 




4.1.5. Selected isotype switched hybridoma clones release MOG-specific antibodies of the 
desired isotype into the supernatant 
Since membrane expression of a new antibody isotype in the 8.18c5 hybridoma cell line does not necessarily 
imply the production of soluble antibodies, we wanted to characterize whether the new cell lines were 
secreting antibodies into the supernatant, and in that case, which antibody isotype was being released. After 
sorting of a single positive 8.18c5 hybridoma cell population expressing the new immunoglobulin in the 
membrane, the isolated hybridoma cells were subcloned using limiting dilution protocols (Figure 11A). 
Dilution of cells until arriving to a concentration of one cell per well allowed us to ensure that the new 
hybridoma cell line derives from a single cell, but also enables us to analyse high numbers of different clones 
at the same time by ELISA. Analysis of the supernatants by ELISA revealed that, while some clones were still 
able to produce IgG1, other clones were producing specifically the new immunoglobulin (Figure 11B), which 
were expanded and cultured for antibody production (Figure 11C). Supernatants were purified by affinity 
chromatography and the eluted fractions were quantified. The purified antibodies were then evaluated by gel 
electrophoresis and western blot (Figure 11D). Gel electrophoresis revealed a molecular weight increase of 
the heavy chain of IgE antibodies compared to IgG1, given the extra C domain found in the IgE structure (Figure 
11D upper). Western blot showed immunoreactivity for 8.18c5 IgE samples in presence of anti-IgE antibodies 
but not in the presence of anti-IgG1 antibodies (Figure 11D bottom). Next, we addressed whether the new 
antibodies were able to bind to their target protein, mMOG. ELISA assays in rmMOG-coated plates confirmed 
the binding of the antibody to MOG, as well as the presence of only antibodies of the IgE isotype (Figure 11E). 
The purified antibodies were further evaluated by FACs analysis using T-mMOG cells, confirming that the new 
antibodies were exclusively of the IgE isotype and that they recognized MOG expressed at the surface of T-
mMOG cells (Figure 11F).  
Following this approach, it was possible to establish 8.18c5 hybridoma cell lines producing IgE, but also 8.18c5 
hybridoma cell lines producing IgG2b. Purified antibodies derived from IgG2b-expressing cells showed 
specificity for mMOG (Figure 12). Sufficient quantities of 8.18c5 IgE and 8.18c5 IgG2b were produced in order 







Figure 11. Newly generated 8.18c5 cell lines secrete antibodies with different isotypes while preserving the antigen 
specificity. A) 8.18c5 IgE-expressing cells were diluted until a 5 cell/ml concentration for single cell subcloning in 96 well-
plates. B) Supernatant from IgE-expressing subclones was tested by rmMOG ELISA for antibody isotype characterization. 
C) Clones expressing exclusively IgE were isolated and expanded for antibody production in PFHM-II.  Supernatants were 
collected and purified by affinity chromatography (GE Healthcare). D) Purified proteins were tested by gel electrophoresis 
(upper) and Western Blot (lower). 1 µg of protein was denatured at 90 °C in β-mercaptoethanol. Electric separation of 
proteins was performed at 100V. For molecular weight characterization, agarose gels were stained with cromassie blue. 
For Western Blot, eluted proteins were tested with anti-IgE and anti-IgG1 antibodies. E) ELISA analysis of 8.18c5 IgG1 and 
IgE antibodies. Purified antibodies from 8.18c5 IgG1 and IgE expressing cell lines were tested with recombinant mMOG 
ELISA-coated plates (4 µg/ml) for IgG1 and downstream-localized isotypes. F) FACs staining for antibody isotype 
confirmation. 1x106 T-mMOG cells were stained with 1 µg of purified antibodies. Antibody isotype was tested with anti-
IgE and anti-IgG1 antibodies. 
 
Figure 12. Characterization of affinity-chromatography purified antibodies from IgG2b expressing 8.18c5 clones. ELISA 
analysis of 8.18c5 IgG1 and IgG2b antibodies. Purified antibodies from 8.18c5 IgG1 and Ig2b expressing cell lines were 
tested with recombinant mMOG ELISA-coated plates (4 µg/ml) for IgG1 and downstream-localized isotypes. 
4.1.6. CRISPR-Cas9 allows the generation of different antibody isotypes in the Z2 hybridoma 
The different aforementioned approaches were also used in order to switch the isotype of the produced 
antibodies in the Z2 hydridoma cell line. This hybridoma is known to produce MOG-specific autoantibodies of 
the IgG2a isotype104, which also binds to the FG-loop of MOG, but the recognized epitope by Z2 is not 
completely identical to  the one recognized by 8.18c5105. Similar to 8.18c5, the Z2 hybridoma cells expressed 
only one type of immunoglobulin isotype at the cell surface (Figure 13). The characterization of the Z2 
hybridoma, as well as the switch to different antibody isotypes using the CRISPR-Cas9 system, were performed 
in our department in a master´s project106. Targeting of the Z2 hybridoma with Cas9-containing gRNAs for the 
IgH upstream sequences of IgE and IgA led to the generation of different hybridoma cell lines expressing one 
of these two immunoglobulins. These Z2-derived cell lines secreted antibodies into the supernatant exclusively 




Figure 13. Z2 hybridoma cells express exclusively antibodies of the IgG2a isotype. FACs staining of Z2 for membrane 
immunoglobulin expression characterization. 1x106 cells were stained with biotin-conjugated IgG1, IgG2b, IgG2a, IgE or 
IgA and revealed with st-APC. Gating strategy in the left side. MFI results of immunoglobulin membrane expression are 
showed in the right panel. 
 
To sum up, using our CRISPR-Cas9 based approach we could generate 8.18c5 cell lines producing MOG-specific 
antibodies of the IgE and IgG2b isotype, in addition to IgG1 antibodies produced by the original 8.18c5 
hybridoma´cells. Furthermore, CRISPR-Cas9 induced isotype switch in the Z2 hybridoma, which originally 
produce MOG-specific IgG2a antibodies, led to the expression and production of soluble IgE and IgA antibodies. 
Chromatography-affinity purified antibodies derived from the different Z2 and 8.18c5 hybridoma cell lines 
were tested for isotype characterization and reactivity against mMOG in the T-mMOG cell line (Figure 14A and 
14B). All the purified antibodies derived from these switched hybridoma cell lines contained only one type of 
antibody isotype. Our results show that production of every antibody isotype found downstream of the IgG1 
genomic constant domain while preserving antibody specificity is possible using a CRISPR-Cas9 based approach. 
Large-scale production of the antibody isotypes depicted in figure 11 was undertaken in order to be able to 







Figure 14. Characterization of newly generated purified antibodies isotypes preserving the same specificity from 8.18c5 
and Z2 hybridomas. FACs staining of T-mMOG cells with purified proteins from different 8.18c5 and Z2 cell lines. 1x106 
T-mMOG cells were stained with 1 µg different purified antibodies (8.18c5 IgG1, IgE and IgG2b; Z2 IgG2a, IgE and IgA). A) 
Gating strategy for characterization of the antibodies binding to MOG and antibody isotype. B) MFI quantification of 
purified antibodies for different isotypes. 1x104 T-mMOG cells were stained with purified antibodies from 8.18c5 and Z2 
lines varying in isotype. Presence of other antibody isotypes was tested with biotin-conjugated antibodies recognizing 
IgG1 and antibody isotypes located downstream.  
4.2. The antibody isotype determines different clinical outcomes in the EAE model 
Previous findings from our department showed that autoantibodies accumulated within CNS antigen-
presenting phagocytes, which presented antigen more efficiently to invading effector T lymphocytes87. This 
resulted in an acceleration of EAE onset and a more severe disease. In these studies, antibodies of the IgG1 
isotype derived from the 8.18c5 hybridoma were used. Since antibody effector functions are conditioned by 
the antibody isotype107-108, we sought to address the role of the antibody isotype in the EAE model. 
4.2.1. MOG-specific IgG1 and IgG2b accelerate the disease onset and enhance disease 
severity in the EAE model 
In order to test whether the antibody isotype has a crucial role in EAE clinical outcome, animals were 
immunized and antibodies were administered shortly before the beginning of the clinical symptoms. 
Compared to the IgG1 isotype control, the original 8.18c5 antibodies of the IgG1 isotype accelerated disease 
onset and enhanced the clinical severity of EAE as expected, both when antibodies were administered 
systemically (intravenously, i.v.) or locally (intrathecally, i.t.) (Figure 15A). These data confirm previous results 
indicating that MOG-specific antibodies have a crucial role in modulating T cell reactivation within the CNS 
rather than in the periphery87. Very similar results were obtained when 8.18c5 IgG2b was administered. 
Compared to the IgG2b isotype control, 8.18c5 IgG2b accelerated disease onset and enhanced disease severity, 
both when administered i.v. and i.t. (Figure 15A). Interestingly, when 8.18c5 IgE was administered either i.v. 
or i.t. shortly before disease onset, the animals did neither show enhanced disease severity nor an accelerated 
disease onset (Figure 16A). Since the half-life of IgE in plasma is shorter in comparison to other isotypes62, we 
administered 8.18c5 IgE on three consecutive days. Triple administration of 8.18c5 IgE did also not lead to 
disease acceleration and increased disease severity, in contrast to both 8.18c5 IgG1 and 8.18c5 IgG2b (Figure 
17). These results show that the disease-accelerating effect of the 8.18c5 antibody in active EAE is influenced 
by the antibody isotype. 
To provide further evidence that MOG-specific antibodies exert their effects in the CNS rather than in the 
periphery, we addressed their effect on disease progression upon administration of different antibody 
isotypes in the passive transfer EAE model, where fully activated T cell blasts do not require further priming in 
order to invade the CNS and induce EAE. In the transfer EAE model, 8.18c5 IgG1 worsened the disease when 
administered i.v. compared to IgG1 isotype control, but also when administered i.t., confirming our previous 
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observations concerning the modulatory effects of antibodies within the CNS87 (Figure 15B). Acceleration of 
disease onset and enhancement of disease severity was also observed in the transfer EAE model upon 
administration of 8.18c5 IgG2b both i.v. or i.t. (Figure 15B). These results further support the role of antibodies 
exerting their effects within the CNS, but also point at a similar role for IgG1 and IgG2b regarding disease-
modifying effects in our model. Similar to the results obtained in the active EAE model, 8.18c5 IgE did not exert 
disease modulatory effects in the transfer EAE model, since animals injected i.v. or i.t. showed a similar clinical 
outcome when administered with 8.18c5 IgE or IgE isotype control (Figure 16B). Taken together, these results 
indicate that antibodies exert their effects within the CNS even after the priming phase, but also that antibody 





Figure 15. 8.18c5 IgG2b reproduce disease onset acceleration and disease severity effect of 8.18c5 IgG1. 8.18c5 IgG1 
(red), IgG2b (blue), IgG1 isotype control (black) or IgG2b isotype control (grey) was intravenously (left) or intrathecally 
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(right) injected on d8 after immunization with 25 µg of MOG35-55 (A), or on d2 after T cell transfer (B). The clinical course 




Figure 16. 8.18c5 IgE does not reproduce disease onset acceleration and disease severity effect of 8.18c5 IgG1. 8.18c5 
IgG1 (red), IgE (green), IgG1 isotype control (black) or IgE isotype control (grey) was intravenously (left) or intrathecally 
(right) injected on d8 after immunization with 25 µg of MOG35-55 (A), or on d2 after T cell transfer (B). The clinical course 
of the disease (top), the day of onset (middle) and the disease incidence (down) are depicted for each model.  
 
 
Figure 17.Triple administration of 8.18c5 IgE does not reproduce disease onset acceleration and disease severity effect 
of 8.18c5 IgG1. 8.18c5 IgE (green) or IgE isotype control (gray) were administered intravenously on d8, d9 and d10 after 
immunization with 25 µg of MOG35-55. The clinical course of the disease (left), day of onset (middle) and disease incidence 
(right) are depicted. 
 
4.2.2. Disease-modulatory effects on EAE mediated by MOG-specific Z2 antibodies are also 
isotype dependent 
In our laboratory, we found that Z2 IgG2a has a similar effect on disease modulation compared to 8.18c5 
IgG1109. Upon administration of 8.18 IgG1 or Z2 IgG2a, the animals developed a more severe disease course 
and an earlier disease onset in comparison to their respective isotype controls (Figure 18). Work from a master 
thesis addressed the question whether CRISPR-Cas9 induced isotype switch of Z2 antibodies would have the 
same effect observed with the 8.18c5 isotypes in the active EAE model106. The results of this study showed 
that the animals administered with 50 µg of Z2 IgG2a developed enhanced disease severity and accelerated 
the day of onset in comparison to IgG2a isotype control, but administration of either 50 µg Z2 IgE or Z2 IgA did 
not reproduce this effect. These results substantiate our observations from the experiments using 8.18c5 
antibodies of different isotypes. Summarizing all results obtained with antibodies of different isotypes derived 
from the 8.18c5 and Z2 hybridoma cell lines, from the panel tested so far only antibodies of the IgG isotype 





Figure 18. Z2 IgG2a reproduce disease onset acceleration and disease severity effect of 8.18c5 IgG1. C57Bl6/J animals 
were intravenously injected with 8.18c5 IgG1 (red), Z2 IgG2a (purple), IgG1 isotype control (black) or IgG2a isotype control 
(grey) on d8 after immunization with 25 µg of MOG35-55. The clinical course of the disease (left), day of onset (middle) and 
disease incidence (right) are depicted. 
4.3. 8.18c5 IgG1 re-activate more efficiently infiltrating T cells than other antibody 
isotypes at the onset of EAE 
Previous results from our department showed that MOG-specific antibodies of the IgG1 isotype accumulate 
in local APCs within the meninges and activate autoreactive T cells more efficiently than control antibodies87. 
We hypothesized that the observed differences regarding the disease modifying effects among different 
antibody isotypes could be a consequence of the potential of different antibody isotypes to reactivate MOG-
specific T cells within the CNS. As a consequence, these cells would produce higher amounts of inflammatory 
mediators and would be more efficiently recruited to the CNS. To address this question, a T cell activation 
reporter mouse line in which the Nur77 protein is coupled to GFP (Nur 77-GFP) was used. Nur77-GFP animals 
express GFP upon TCR engagement but not by cytokine signalling101. GFP expression is temporary, peaking 
between 12 and 24 hours after TCR stimulation, enabling us to detect T cell activation directly by FACs analysis 
during this timeframe. T cells isolated from nur77-GFP animals were used for induction of transfer EAE. The 
donor cells were injected into CD45.1 congenic recipients, and 8.18c5 IgG1, IgG2b and IgE, or their respective 
isotype controls, were administered i.v. on day 2 post transfer. The animals were sacrificed at disease onset 
and the percentage of GFP+ T cells was assessed by FACs analysis. Additionally, GFP+ and GFP- cells were 
sorted to compare cytokine expression levels directly on a per cell basis.  
While in the blood no GFP+ T cells were found, activated GFP+ T cells were clearly present in the meninges 
and spinal cord parenchyma (Figure 19A and 19B). In the meninges, the percentage of GFP positive cells was 
higher upon administration of 8.18c5 IgG1 compared to IgG1 isotype control. Administration of 8.18c5 IgG2b 
led to a non-significant enhancement of activated cells. However, this was not the case upon administration 
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of 8.18c5 IgE, which induced similar percentages of GFP positive T cells in the meninges. Interestingly, 
administration of 8.18c5 IgG2b led to higher percentages of activated T cells compared to 8.18c5 IgE. In the 
spinal cord parenchyma, significantly higher numbers of activated CD4+ T cells upon administration of 8.18c5 
IgG1 were observed, while similar results to the meningeal compartment were obtained upon administration 
of 8.18c5 IgG2b and IgE. At the cellular level, cytokine expression in GFP positive cells was increased compared 
to non-activated (GFP-) T cells, but no differences were observed among the different 8.18c5 antibody isotypes 
and their isotype controls in any analysed tissue. These results indicate that 8.18c5 IgG1 isotype is able to 
activate quantitatively higher numbers of infiltrating T cells compared to 8.18c5 IgE, but the expression levels 
of pro-inflammatory cytokines in activated T cells were not enhanced on a per-cell basis among the activated 






Figure 19. 8.18c5 IgG1 reactivate quantitavely more autoreactive effector T cells than its antibody isotype counterparts 
at the onset of EAE. EAE was induced by adoptive transfer of encephalitogenic MOG-specific T cells derived from Nur77-
GFP animals. Antibodies were injected i.v. on d2 post transfer. Upon appearance of the first clinical symptoms, CD4+ T 
cells were sorted from blood, meninges and spinal cord. A) Gating strategy followed for cell sorting. Nur77-GFP T cells 
from donor animals were identified by their expression of CD3, CD4 and CD45.2. Activated and non-activated CD4+ T cells 
were distinguished by their GFP expression as indicated. B) Percentage of GFP+ T cells in blood, meninges and spinal cord 
parenchyma in 8.18c5 (IgG1 dark red, n=5; IgG2b dark blue, n=4; IgE dark green, n=4) or isotype control (IgG1 isotype 
control light red, n=5; IgG2b isotype control light blue, n=4; IgE isotype control light green, n=4) treated animals at disease 
onset. C) Expression of the pro-inflammatory cytokines IFNγ (top), GM-CSF (middle) and IL-17 (bottom) of non-activated 
(left panel) and activated (right panel) CD4+ T cells determined by qRT-PCR (n=2-5 per case). 
4.4. Antibody isotype determines CNS demyelination and macrophage recruitment 
to the CNS in EAE  
4.4.1. Antibody-driven CNS demyelination is dose- and isotype-dependent 
Direct binding of MOG-specific antibodies to myelin can contribute to demyelination through ADCC or 
activation of the complement cascade38,110. Moreover, antibodies opsonizing myelin debris can be recognized 
by resident glial cells and infiltrating myeloid cells through their Fc receptors, which can trigger further immune 
responses resulting in CNS tissue destruction. Our previous results using relatively low concentrations of 
antibodies (50 µg /animal) showed that MOG-specific IgG1 did not cause severe demyelination in preclinical 
EAE stages independently of CNS inflammation87. In contrast, other studies found enhanced demyelination at 
later EAE stages in 2D2 animals, which contain MOG-specific T cells, upon administration of both Th serum 
and 150 µg of 8.18c5 IgG186. These data raised the question whether increasing antibody dosing would 
enhance spinal cord demyelination in WT animals at later time points, and whether the antibody isotype could 
have an effect on demyelination. 
In order to address this question, animals were immunized and administered with increasing doses of 8.18c5 
IgG1 or IgG1 isotype control, and spinal cord demyelination was evaluated by LFB staining in paraffin-
embedded sections. At the lumbar level, the most affected CNS region by demyelination in our model, 8.18c5 
IgG1 antibodies did not enhance spinal cord demyelination at a dose of 50 µg compared to IgG1 isotype control 
(Figure 20A top and 20B). However, i.v. injection of 125 µg and 250 µg of 8.18c5 IgG1 significantly enhanced 
spinal cord demyelination, reaching a peak of 18% demyelinated area of the white matter at the maximum 
dose. These results indicate that triggering certain antibody effector functions require to overcome a minimum 
threshold in our EAE model. Administration of increasing concentrations of 8.18c5 IgE did not lead to an 
enhancement of spinal cord demyelination in a dose-response manner (Figure 20A top and 20B). In contrast, 
administration of 50 µg of 8.18c5 IgG2b induced 20% demyelination of the white matter of the spinal cord, a 
percentage significantly higher than the one induced upon administration of 50 µg of 8.18c5 IgG1. Even though 
a dose of 125 µg of 8.18c5 IgG2b did not enhanced spinal cord demyelination compared with 50 µg of 8.18c5 
IgG2b, animals receiving 250 µg of 8.18c5 IgG2b showed enhanced spinal cord demyelination compared to 
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the minimum dose of 8.18c5 IgG2b, reaching a peak of 30% of the white matter (Figure 20A top and 20B). The 
latter dose also induced higher spinal cord demyelination compared to the maximum dose of 8.18c5 IgG1. 
These results indicate the 8.18c5 IgG2b is more efficient in targeting spinal cord demyelination than 8.18c5 
IgG1, and that IgE cannot trigger this process. 
Previous studies in Lewis rats showed that Z2 IgG2a has a higher demyelination capacity than 8.18c5 IgG1 
antibodies84. These observations were based on the administration of high antibody amounts (3 mg of 
antibodies per animal). Therefore, the demyelinating potential of different doses of Z2 IgG2a antibodies in our 
system was investigated. Compared to IgG2a isotype control, 50 µg of Z2 IgG2a did enhance spinal cord 
demyelination, reaching a peak of 16% of the white matter (Figure 20A top and 20B). These results indicate 
that also at low doses, Z2 IgG2a antibodies have more demyelinating potential than 8.18c5 IgG1 antibodies. 
Increasing concentrations of Z2 IgG2a enhanced spinal cord demyelination in a dose-dependent manner, 
reaching a peak of 30% demyelination of the white matter at the highest dose (Figure 20A top and 20B). In 
addition, the Z2 antibody isotype seemed to be crucial for demyelination, since no dose-dependency pattern 
was observed when animals received increasing doses of Z2 IgE and IgA (Figure 20A top and 20B). In line with 
the results obtained with the 8.18c5 antibodies, an enhancement of spinal cord demyelination could be 
observed only in the case when Z2 antibodies of the IgG isotype were administered. Statistical comparisons 
are summarized in Table 5.  
The observed patterns for all these antibody isotypes were further confirmed at the thoracic level, although 
the animals showed lower spinal cord demyelination percentages in this region. At the cervical level, 250 µg 
of Z2 IgG2a still enhanced spinal cord demyelination compared to IgG2a isotype control. Other 8.18c5 and Z2 
antibody isotypes did not induce additional demyelination in this region of the spinal cord (Figure 20A).  
Confirming our previous results regarding the acceleration effect of MOG-specific autoantibodies, when 
assessing the clinical course of the disease in these experiments, disease acceleration was only observed upon 
administration of different IgG antibody isotypes, but not by IgE or IgAs (Figure 21). This acceleration effect of 
IgGs was independent of the dose administered. Higher concentrations of IgE and Z2 IgA were not able to 
induce an earlier disease onset, providing further support to the idea that disease acceleration is an IgG-driven 







Figure 20. IgGs enhance spinal cord demyelination more efficiently than other antibody isotypes. C57Bl6/J were 
immunized with 50 µg of MOG35-55 and injected intravenously on d8 with 50, 125 or 250 µg of the indicated 8.18c5, Z2 
antibodies, or isotype control. Animals were sacrificed at the peak of the disease (Scores 6-7) and spinal cord sections 
were stained with LFB, anti-MAC3 or anti-CD3 antibodies. A) Top: quantification of the spinal cord demyelination 
percentage at lumbar (left), thoracic (middle) and cervical (right) regions. Middle: quantification of the percentage of 
area occupied by the macrophage marker MAC-3 in the spinal cord at lumbar (left), thoracic (middle) and cervical (right) 
regions. Bottom: quantification of CD3 positive T cell infiltrates in the spinal cord at at lumbar (left), thoracic (middle) and 
cervical (right) regions. Groups of 3 columns in every experimental case show increasing antibody dosing: 50 µg (first 
column), 125 µg (second column), and 250 µg (third column). B) Representative LFB-stained spinal cord sections at the 
lumbar region are depicted. Left panel show 8.18c5 antibodies or isotype control examples. Right panel show Z2 
antibodies or isotype control examples. Arrows point at an example of demyelinating lesion considered for the analysis 
of the LFB staining. Scale bar: 200 µm. 
 
 
Figure 21. IgGs accelerate disease onset more efficiently than other isotypes independently of the administered dose. 
C57Bl6/J were immunized with 50 µg of MOG35-55 and injected intravenously on d8 with 50, 125 or 250 µg of the indicated 
8.18c5, Z2 antibodies, or isotype control. Clinical score was evaluated daily and day of disease onset is depicted in the 
figure. IgG1 isotype control 50-125-250 µg (black, n=4-5), 8.18c5 IgG1 50-125-250 µg (red, n=5-6), 8.18c5 IgE 50-125-250 
µg (green, n=4-5), 8.18c5 IgG2b 50-125-250 µg (blue, n=5-6), IgG2a isotype control 50-125-250 µg (black, n=3-5), Z2 IgG2a 
50-125-250 µg (purple, n= 5-6), Z2 IgE 50-125-250 µg (green, n=4-5), Z2 IgA 50-125-250 µg (pink, n= 4-5). 
4.4.2. Macrophage and T cell infiltration is not different upon administration of low doses of 
different 8.18c5 or Z2 antibody isotypes 
In the EAE model, infiltrating T-cells and macrophages, and their inflammatory mediators, mediate CNS 
inflammatory damage leading to the CNS demyelination11,111. Consequently, we evaluated macrophage and T 
cell infiltration in the CNS upon administration of different antibody isotypes following the experimental 
design described in the previous chapter. Macrophage infiltration was evaluated by quantification of the 
percentage of the area of the white matter occupied by MAC-3 positive cells in spinal cord sections. 
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At the lumbar spinal cord, 8.18c5 IgG1 did not enhanced the percentage of the area occupied by MAC-3 
positive cells compared to IgG1 isotype control at any administered dose (Figure 20A, middle part). Similar 
results were obtained upon administration of 8.18c5 IgE. Although administration of 50 µg of 8.18c5 IgG2b 
did not enhanced spinal cord MAC-3 staining, the highest dose promoted an enhancement of MAC-3 positive 
cells compared to the same dose of 8.18c5 IgG1 (one way ANOVA, p=0.0005), reaching a peak of approximately 
7% occupied area of the white matter. 
Administration of either 50 µg or 125 µg of Z2 IgG2a did not lead to an increased percentage of MAC-3 positive 
cells within the CNS tissue (Figure 20A). However, i.v. injection of 250 µg of Z2 IgG2a enhanced the percentage 
of MAC-3 positive cells compared to IgG2a isotype control, reaching a peak of 7%. Additionally, administration 
of Z2 IgE and IgA did not lead to enhanced MAC-3 staining at any administered dose. Since increased 
percentages of MAC-3 positive cells were only observed upon administration of high amounts of 8.18c5 IgG2b 
and Z2 IgG2a, while low doses of these antibodies already enhanced spinal cord demyelination, these results 
indicate that enhanced demyelination of the spinal cord is not strongly correlated to higher numbers of 
macrophages present within the CNS. 
Infiltrating T cells numbers and macrophage recruitment to the CNS are closely related in the EAE model112. 
Since T cell recruitment could be affected by the administration of MOG antibodies varying in their isotype, T 
cell infiltration was assessed by quantification of spinal cord sections stained with antibodies specific for CD3. 
No differences were found in T cell infiltration at any dose upon administration of 8.18c5 isotypes (Figure 20A, 
lower part). Upon administration of Z2 IgG2a similar results were obtained, showing that Z2 isotypes did not 
induce the recruitment of higher numbers of CD3 positive T cells at any administered dose (Figure 20A). These 
results indicate that different antibody isotypes recruit similar numbers of T cells to the CNS at the peak of the 
disease. Nevertheless, the presence of higher numbers of MAC-3 positive cells points at a potential role for 











Table 5. Percentage of demyelination statistical analysis at the lumbar spinal cord; experiment depicted in figure 14. 
One-way ANOVA of 8.18c5 and Z2 antibody isotypes or isotype control, independent from each other, is depicted. The 








 Statistical significance  Statistical significance 
IgG1 isotype control  IgG2a isotype control  
50 µg vs 125 µg ns 50 µg vs 125 µg ns 
50 µg vs 250 µg ns 50 µg vs 250 µg ns 
125 µg vs 250 µg ns 125 µg vs 250 µg ns 
8.18c5 IgG1  Z2 IgG2a  
50 µg vs 125 µg ns 50 µg vs 125 µg ns 
50 µg vs 250 µg *** 50 µg vs 250 µg **** 
125 µg vs 250 µg ns 125 µg vs 250 µg ** 
8.18c5 IgE  Z2 IgE  
50 µg vs 125 µg ns 50 µg vs 125 µg ns 
50 µg vs 250 µg ns 50 µg vs 250 µg ns 
125 µg vs 250 µg ns 125 µg vs 250 µg ns 
8.18c5 IgG2b  Z2 IgA  
50 µg vs 125 µg ns 50 µg vs 125 µg ns 
50 µg vs 250 µg ns 50 µg vs 250 µg ns 







 Statistical significance  Statistical significance 
8.18c5 IgG1 vs 
IgG1 isotype control 
 Z2 IgG2a vs 
IgG2a isotype control 
 
50 µg ns 50 µg ** 
125 µg *** 125 µg **** 
250 µg **** 250 µg **** 
8.18c5 IgG1 vs IgE  Z2 IgG2a vs IgE  
50 µg * 50 µg * 
125 µg **** 125 µg *** 
250 µg **** 250 µg **** 
8.18c5 IgG1 vs IgG2b  Z2 IgG2a vs IgA  
50 µg ** 50 µg * 
125 µg * 125 µg ** 
250 µg ** 250 µg **** 
8.18c5 IgE vs IgG2b  Z2 IgE vs IgA  
50 µg **** 50 µg ns 
125 µg **** 125 µg ns 






4.4.3. Intrathecal administration of low doses of 8.18c5 antibody isotypes also enhance CNS 
demyelination  
Since we observed enhanced demyelination upon i.v. injection of high doses of 8.18c5 IgG1, as well as at every 
administered dose of 8.18c5 IgG2b, the effect of 8.18c5 isotypes when administered directly into the CNS at 
two different doses (10 µg and 50 µg) was investigated. In this experimental setup, animals were injected with 
either IgG1 isotype control or 8.18c5 antibody isotypes i.t. before disease onset, and sacrificed at the peak of 
the disease. 8.18c5 IgG1 did not enhanced demyelination compared to isotype control when a dose of 10 µg 
was i.t. administered (Figure 22A and 22B). However, 50 µg of 8.18c5 IgG1 did enhanced demyelination 
compared to IgG1 isotype control. These results go in line with our observations in the i.v. administration 
context, and support the hypotheses that higher concentrations of 8.18c5 IgG1 are required for this antibody 
isotype in order to exert demyelination efficiently. 8.18c5 IgE did not show increasing demyelination capacity 
upon increasing dosage (Figure 22A and 22B). Administration of 10 µg of 8.18c5 IgG2b enhanced spinal cord 
demyelination compared to the same dose of 8.18c5 IgG1, reproducing the effect observed after i.v. 
administration of MOG-specific IgG2b antibodies. However, the demyelination percentage after 
administration of 50 µg of 8.18c5 IgG2b was not significantly different from the one obtained with the lower 
dose and was also similar to the same dose of 8.18c5 IgG1. Taken together these results further support the 
idea that both antibody dosage and antibody isotype determines the outcome of pathological effector 




Figure 22. 8.18c5 IgGs enhance spinal cord demyelination when administered directly into the CNS. C57Bl6/J were 
immunized with 50 µg of MOG35-55 and injected intrathecally on d8 with 10 or 50 µg. Animals were sacrificed at the peak 
of the disease (Scores 6-7) and spinal cord sections were stained with LFB. A) Quantification of spinal cord demyelination 
percentage at the lumbar (left), thoracic (middle) and cervical (right) spinal cord regions. B) Representative LFB-stained 
spinal cord sections at the lumbar region are depicted. Arrows point at an example of demyelinating lesion considered 









4.4.4. Administration of 8.18c5 antibody isotypes at the peak of EAE does not lead to 
enhanced demyelination 
In our model, crucial immune processes such as priming of cells in the draining lymph nodes as well as T-cell 
reactivation in the meninges by local APCs have already occurred at the peak of the disease. Since we observed 
variations in the demyelination potential of different antibody isotypes when administered both i.v. or i.t. at 
early time points, which were not completely correlated to infiltration of macrophages and T cells, we 
investigated whether enhanced demyelination could also be observed upon antibody administration at later 
time points. In order to address this question, C57Bl6/J animals were immunized with MOG35-55 and injected 
i.t. with 10 µg of different 8.18c5 antibody isotypes or IgG1 isotype control at the peak of the disease. 24 hours 
after i.t. injections we did not find significant differences in demyelination between 8.18c5 IgG1 and IgG1 
isotype control (Figure 23A and 23B, upper part). Moreover, no differences in spinal cord demyelination were 
found upon administration of 8.18c5 IgE and IgG2b compared to 8.18c5 IgG1. Quantification of MAC-3 staining 
and number of infiltrating CD3 positive T cells did also show no difference among the different 8.18c5 
antibodies. Since the chosen time point could be too early to observe any effects, these parameters were 
addressed 3 days after antibody i.t. injection at the peak of EAE. Similar to the previous experiment, 
demyelination was not significantly enhanced three days after administration of antibodies, although a clear 
tendency towards an enhanced demyelination could be observed upon administration of 8.18c5 IgG2b (Figure 
23A and 23B, lower part). Moreover, no differences were found in the area covered by MAC-3 positive cells 
or numbers of infiltrating CD3 positive cells. These results indicate that in spite of the slight enhancement that 
can be observed upon administration of 8.18c5 IgG2b, 8.18c5 antibodies exert their pathogenic functions 




Figure 23. Intrathecal administration of 8.18c5 antibodies or isotype control at the peak of EAE does not lead to 
enhanced spinal cord demyelination. C57Bl6/J were immunized with 50 µg of MOG35-55 and injected intrathecally at the 
peak of the disease (Scores 6-7) with 10 µg of 8.18c5 IgG1, IgE, IgG2b or IgG1 isotype control. Animals were sacrified 24 
hours later (upper panels) or 72 hours later (lower panels). A) Quantification of spinal cord demyelination percentage at 
the lumbar (left), thoracic (middle) and cervical (right) regions. B) Representative LFB-stained spinal cord sections at the 
lumbar region are depicted. Arrows point at an example of demyelinating lesion considered for the analysis of the LFB 







4.5. Antibody-dependent effector mechanisms within the CNS are dependent on Fc 
receptors expression  
4.5.1. MOG-specific IgG1 autoantibodies enhance CNS demyelination in Fcγ receptor knock 
out animals but do not accelerate EAE onset 
Autoantibodies can target myelin structures upon generation of immunocomplexes and their subsequent 
recognition by cells expressing Fc receptors, which would ultimately exert CNS damage through ADCC. We 
reasoned that isotype-dependent demyelination patterns might be modified upon genetic removal of 
different Fc receptors. To this end, several KO models for different Fc receptors were tested. The animal 
models used in this experimental setup were the KO for the Fc neonatal receptor (FcRn), which is implicated 
in recycling and intracellular processing of IgGs and consequently increasing the half-life time of 
immunoglobulins113; KO animals for the common γ-chain + FcγRIIB, where activating FcγRs I, III and IV, and the 
inhibitory FcγRIIB are affected; KO animals for the alpha chains of FcγRs I and III; and KO animals for the alpha 
chains of FcγRI, IIB, III and IV (FcγRI-IV). The animals were immunized with 50 µg of MOG35-55 plus PTX, and 
administered i.v. with 50 µg 8.18c5 IgG1 or IgG1 isotype control shortly before the clinical onset of the disease. 
The acceleration of disease onset observed upon administration of 8.18c5 IgG1 in WT mice was reproduced in 
all the KO models, with the exception of the FcγRI-IV KO animals (Figure 24A), supporting previous 
observations from our department109. These latter animals showed no differences in the day of onset of EAE 
compared to isotype control, while this effect was still present in both WT animals and mice in which only 
parts of the FcγR repertoire were deleted. Demyelination was not enhanced upon administration of 8.18c5 
IgG1 in WT animals (Figure 24B and 24C), similar to our previous observations. FcRn KO, FcR common-γ + 
FcγRIIB KO and FcγRI+III KO animals did also not show enhanced demyelination when administered with 
8.18c5 IgG1. However, a significant enhancement of demyelination was found in FcγRI-IV KO animals (Figure 
24B and 24C). Intriguingly, these animals showed already enhanced demyelination compared to WT animals 
when treated with the isotype control antibody, indicating that CNS demyelination is generally enhanced upon 
removal of the Fcγ receptor alpha chains. Upon treatment with MOG-specific antibodies, FcγRI-IV KO mice 
showed a highly significant increase in demyelination (Figure 24B and 24C), suggesting that 8.18c5 IgG1 
antibodies are able to exert higher amounts of demyelination in the absence of Fcγ receptors.  
Importantly, the abrogation of disease acceleration by 8.18c5 IgG1 in FcγRI-IV KO animals together with the 
enhanced spinal cord demyelination suggest that disease acceleration and demyelination are driven by 
different mechanisms. These results also suggest that the role of antibodies in specific effector mechanisms 
can be modified through the ablation of certain molecular cues, resulting in different types of effector 




Finally, quantification of MAC3 positive cells and CD3 positive cells in these samples did not show any 
significant difference among the KO animals tested, indicating the macrophage and T cell recruitment are not 
in principle responsible for the observed differences regarding EAE disease onset and enhanced demyelination 






Figure 24. 8.18c5 IgG1 enhance spinal cord demyelination more efficiently upon knock-out of the activating Fc 
receptors alpha chain. C57Bl6/J WT, FcyR I-III-IV KO, FcNR KO,  FcyR I-III and common y chain KO animals were immunized 
with 50 µg of MOG35-55 and intravenously injected with 50 µg of 8.18c5 IgG1 or IgG1 isotype control. A) EAE clinical course 
of WT animals vs the corresponding KO model (left), day of onset (right upper), and disease incidence (right lower). EAE 
curves represent two independent experiments for WT and FcyR I-III-IV KO, and one experiment for the other KO models. 
B) Animals from A) were sacrificed at the peak of the disease and spinal cord sections were stained with LFB, and anti-
MAC3 and anti-CD3 antibodies. Quantification of spinal cord demyelination percentage at the different spinal cord levels 
(upper). Quantification of area occupied by the MAC-3 staining (middle). Quantification of CD3 positive infiltrates at the 
spinal cord (lower). C) Representative LFB-stained spinal cord sections from the different experimental groups at the 
lumbar region are depicted. Arrows point at an example of demyelinating lesion considered for the analysis of the LFB 
staining. Scale bar: 200 µm. 
4.5.2. Enhanced demyelination in FcγRI-IV knock out animals is isotype dependent 
Our observations concerning disease acceleration and demyelination in the FcγRI-IV knock out animals using 
low doses of 8.18c5 IgG1 aroused the hypothesis that antibody isotypes that had been previously 
demonstrated to exert disease acceleration effects would not be able to perform the same effects in these 
animals. Furthermore, efficient demyelinating antibodies could also have higher demyelination potential in 
absence of the Fcγ receptors. To asses this point, WT and FcγRI-IV knock out animals were immunized with 50 
µg of MOG35-55 and treated with 50 µg of 8.18c5 antibody isotypes shortly before disease onset. Accelerated 
disease onset upon administration of any antibody isotype was not observed in these animals, supporting the 
hypothesis that this effect is dependent on the presence of Fcγ receptors, and not an antibody isotype-driven 
process (Figure 25A). In line with the previous results, an enhanced demyelination in FcγRI-IV KO animals 
treated with the IgG1 isotype control antibody compared to WT animals was observed, supporting the idea 
that in these animals there is a higher predisposition for demyelination. Additionally, 8.18c5 IgG1 did not 
induce a significant enhancement of spinal cord demyelination in the WT animals, while it did in the FcγRI-IV 
KO animals (Figure 25B), also reproducing the previous observations. Administration of 8.18c5 IgE did not 
enhance demyelination compared to 8.18c5 IgG1, confirming the low demyelination potential of this antibody 
also in this model. FcγRI-IV KO animals injected with 8.18c5 IgG2b also presented high levels of demyelination, 
but the degree of demyelination was comparable to the one seen in 8.18c5 IgG1 injected animals. Therefore, 
the demyelination potential of these two antibody isotypes seems to be comparable at lower doses in this 
animal model. In addition, quantification of macrophage and T cell infiltration was also not different in this 
experimental setup (Figure 25A). Taken together, these results indicate that the demyelinating potential of 
the antibodies can be modified upon ablation of Fcγ receptor expression, but this demyelinating potential is 




Figure 25. IgGs enhance spinal cord demyelination in Fc receptors alpha chain Knock-out animals more efficiently than 
other antibody isotypes. C57Bl6/J WT or FcyR I-III-IV KO were immunized with 50 µg of MOG35-55 and intravenously 
injected with 50 µg of 8.18c5 IgG1, IgE, IgG2b or IgG1 isotype control. A) The clinical course of the disease (left), the day 
of onset (middle) and the disease incidence (right) are depicted. B) Animals were sacrificed at the peak of the disease 
and spinal cord sections were stained with LFB, and anti-MAC3 and anti-CD3 antibodies. Quantification of spinal cord 
demyelination percentage at the different spinal cord levels (left). Quantification of area occupied by the MAC-3 staining 
(middle). Quantification of CD3 positive infiltrates at the spinal cord (right). C) Representative LFB-stained spinal cord 
sections from the different experimental groups at the lumbar region are depicted. Arrows point at an example of 






4.6. Enzymatic cleavage of the antibody glycosylation pattern modifies the clinical 
outcome of EAE 
Further molecular properties of the antibodies have been shown to have crucial roles for their effector 
function, such as the antibody glycosylation pattern. In particular, glycosylation motifs located at the Asn 297 
have been shown to exert crucial effects in the recognition of the Fc fragment by Fc receptors, and for C1q 
complement subunit binding to the antibodies, consequently triggering the activation of the classical 
complement pathway during the immune response103-114. We investigated whether enzymatic digestion of the 
glycosylation pattern of the 8.18c5 IgG1 antibody could influence the disease progression of EAE animals. To 
this end, 100 µg of 8.18c5 IgG1 and IgG1 isotype control were processed for glycosylation removal under non-
denaturing conditions (Figure 26A). Successful glycosylation removal was confirmed by gel electrophoresis. 
Enzymatic glycosylation removal did not impair the acceleration effect observed upon administration of 8.18c5 
IgG1 compared to isotype control (Figure 26B). However, a slight non-significant decrease in disease severity 
was observed. These results indicate that modification of other molecular properties of antibodies such as 
glycosylation pattern can have an effect in our EAE model, but not sufficient to abrogate the observed disease 
acceleration effects. 
 
Figure 26. Removal of 8.18c5 IgG1 glycosylation motifs induce a slight decrease of EAE disease severity. A) 100 µg of 
8.18c5 IgG1 or IgG1 isotype control  were deglycosylated under non-denaturing conditions with Protein Deglycosylation 
Mix II (New England Biolabs). Glycosylation removal of 8.18c5 IgG1 or IgG1 isotype control was confirmed by gel 
electrophoresis. B) C57Bl6/J animals were intravenously injected with 8.18c5 IgG1 (red), deglycosylated 8.18c5 IgG1 
(orange), IgG1 isotype control (black) or deglycosylated IgG1 isotype control (grey) on d8 after immunization with MOG35-




Although autoreactive CNS-specific effector T cells are thought to be the main cell type responsible for the 
initiation of MS, increasing evidence suggests that B cells also play an essential role in the disease´s 
pathogenesis, as well as in its animal model EAE115,116. The aim of this project was to elucidate the role of the 
antibody isotype in antibody-mediated effector mechanisms within the CNS. Since antibodies of different 
isotypes are known to exert different effector functions due to their structure and molecular properties108,103, 
we sought to produce different antibody isotypes through genetic engineering of hybridoma cell lines, 
ensuring the maintenance of important post-translational modifications for antibody effector function such 
as the glycosylation pattern. A CRISPR-Cas9 system was designed in order to switch the expressed isotype in 
the 8.18c5 and Z2 hybridoma cell lines, which led to the production of different antibody isotypes while 
preserving their specificity. Using these isotypes, we could show that both antibody-mediated acceleration of 
EAE onset and CNS demyelination were isotype dependent. Furthermore, we addressed the role of the Fcγ 
receptors mediating antibody effector functions, and we could show that the genetic removal of all FcγRs 
abrogated the antibody-dependent disease acceleration effect, but potentiated CNS demyelination. 
The CRISPR-Cas9 technology has been widely used in recent years in order to modify the genetic architecture 
of different target organisms and cell lines. Previous reports indicated that Cas9 upstream targeting of the 
heavy chain genes codifying for different antibody isotypes lead to class switch in hybridoma cell lines45. 
Following a similar strategy, we were able to switch the isotype expressed by the 8.18c5 and Z2 hybridoma 
cell lines, which are known to produce demyelinating antibodies against MOG of the IgG1 and IgG2a isotype, 
respectively84. The purified antibodies from switched 8.18c5 and Z2 cell lines were positive for the desired 
isotype and additionally they preserved the specificity for MOG, as we confirmed by WB, ELISA and by FACs 
analysis using T-mMOG cells (Figure 11, 12 and 14). We were able to generate IgE and IgG2b from the 8.18c5 
hybridoma, and additionally this system allowed us to produce IgE and IgA in the Z2 hybridoma. Our 
experiments confirmed the results from previous studies reporting the possibility of driving isotype switch in 
cell lines while preserving the original antigen specificity.  
CSR recombination implies the excision of gDNA regions contained between the Cµ and the expressed isotype 
(Figure 2)43. Considering the gDNA organization at the heavy chain locus of 8.18c5 and Z2 hybridoma cell lines, 
it is not possible to produce the IgM and IgG3 isotypes in the 8.18c5 hybridoma using our CRISPR-Cas9 system, 
as well as the IgM, IgG3, IgG1 and IgG2b antibody isotypes in the Z2 hybridoma by this approach. Therefore, 
to produce those isotypes, the introduction of gDNA sequences codifying for the heavy chains of these isotypes 
by gene knock in is required while mutating the first constant exon domain of the next isotype at the same 
time. However, knock in approaches can induce DNA damage and cell death in a later stage, since long 
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homologous regions are necessary for recombination into the target gDNA sequence117,118. A CRISPR-Cas9 
targeting approach for gene knock in based on 20 nucleotides has been recently published, namely the CRISPR-
Cas9 mediated homology-independent targeted integration (HITI)119. The HITI approach ensures the 
introduction of the desired DNA construct in the forward orientation, enabling the introduction of big DNA 
fragments without the previous requirement of long recombination regions, resulting in reduced cellular stress 
that might lead to cell death. Consequently, the HITI approach seems to be a suitable method for the 
generation of the remaining isotypes that need to be introduced into our hybridoma cell lines. 
Within the CNS, antibodies can exert several effector mechanisms leading to CNS inflammation and nervous 
tissue destruction. These mechanisms include enhanced phagocytosis of immune complexes by meningeal 
cells, resulting in an increased T cell activation and disease acceleration, and direct binding to myelin, thereby 
enhancing CNS demyelination85. Additionally, antibodies might activate astrocytes and microglia, triggering 
their release of pro-inflammatory factors, which would induce the recruitment of more immune cells from the 
blood stream87. Taking these antibody effector mechanisms within the CNS into consideration, this study 
assessed the role of the antibody isotype in disease aggravation and T cell activation, as well as in CNS 
demyelination. 
Linington and collaborators described the so-called “two hit model” for CNS autoimmunity92,120, where 
encephalitogenic T cells initiate the inflammation and promote the disturbance of the blood-brain barrier and, 
as a consequence, anti-MOG autoantibodies would be able to access the CNS and exert damage to the myelin 
sheaths, aggravating the disease. The increased disease severity has been long considered to be due to 
enhanced demyelination and CNS tissue destruction, since autoantibodies can damage myelin structures 
through ADCC or activation of the complement cascade92. Although previous studies attributed special 
emphasis to the demyelinating potential of MOG autoantibodies, recent results from our laboratory showed 
that the role of demyelination by MOG-specific antibodies was not crucial when applied at low doses. Rather, 
the presence of MOG-specific autoantibodies accelerated the entry of autoreactive effector T cells into the 
CNS, leading to an earlier disease onset and disease aggravation87. These discrepancies could be explained by 
the fact that, in comparison to other studies where the administered doses of MOG-antibodies were relatively 
high (30 µg/g i.v. and 200 µg/g i.p.), our system is characterized by the administration of relatively low antibody 
doses (50 µg/mouse i.v. and 10 µg/mouse i.t.). Therefore, our data indicate that, in addition to the role of 
demyelination in disease exacerbation, further mechanisms through which autoantibodies promote EAE 
development should be considered. For that reason, we sought to address the role of antibodies in both the 




Our experiments in the active and transfer EAE models show that the disease acceleration effect was inducible 
upon administration of MOG-specific IgGs of different subclasses (IgG1, IgG2a and IgG2b), but not by IgE and 
IgA (Figure 15, 16, 18 and 21). Furthermore, animals injected with IgGs showed an earlier disease onset both 
when MOG-specific IgGs were administered i.v. and i.t., independently of the IgG subclass. These results 
indicate that, on the one hand, autoantibody-driven disease acceleration seems to be isotype dependent. On 
the other hand, these experiments confirm that the disease accelerating effect of MOG antibodies is a 
phenomena occurring within the CNS rather than in the periphery87, in contrast to other studies which 
highlight the importance of MOG-specific antibodies for T cell priming at the peripheral and CNS draining 
lymph nodes86. These studies reported disease-accelerating effects of MOG autoantibodies, where 2D2 and 
WT recipients were injected with serum from animals whose BCR is restricted to MOG (Th mice)86. The serum 
of these animals contains antibodies against MOG of different isotypes, being IgG2a the most frequent 
antibodies found in these samples32,87, and 58% of double transgenic animals harbouring MOG-specific T and 
B cells develop spontaneous disease121,18. The crucial role of MOG-specific antibodies regarding disease 
acceleration and spontaneous disease development has been previously described using animals harbouring 
mainly antibodies of the IgG isotype, providing further support to our observations. To our knowledge, in the 
current study it is the first time that the role of specific and well-defined isotypes in triggering disease-
modifying effects has been investigated.  
We reasoned that different clinical outcomes upon administration of different isotypes could be due to 
differences in autoreactive T cell re-activation within the CNS. Binding of autoantibodies to their target antigen, 
and subsequent internalization of these immune complexes by APCs in a Fc-receptor dependent-manner, 
could have a more efficient reactivation of autoreactive effector T cells within the CNS as a consequence, 
leading to an earlier disease onset. In order to investigate this hypothesis, the T-cell activation in WT animals 
transferred with T cells from Nur77-GFP animals was measured by flow cytometry. In this set up, activated T 
cells are fluorescently detectable by FACs upon TCR stimulation, but not other stimuli such as cytokine or 
chemokine signalling101. Increased percentages of activated T cells in the spinal cord parenchyma and 
meninges were found upon administration of MOG-specific IgG1 at disease onset (Figure 19). Furthermore, 
administration of IgG2b led to a non-significant tendency towards an enhancement of the percentage of CD4+ 
GFP T cells. Nevertheless, since IgG2b induced disease acceleration in the EAE experiments, further 
experiments are required to clarify the role of IgG2b in T cell activation within the CNS. In contrast, 
administration of MOG-specific IgE did not lead to higher percentages of activated T cells within the meninges 
and spinal cord compared to its respective isotype control. Of note, antibody isotypes have different affinity 
for the Fc receptors, which might help to explain differences regarding T cell reactivation. For example, while 
IgG1 antibodies are reported to efficiently bind FcγRs but not to efficiently fix complement, IgG2b antibodies 
are known to efficiently perform in both processes122. This opens the possibility that IgG1-myelin immune 
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complexes are mainly captured by APCs which would present antigen more efficiently to autoreactive T cells, 
being IgG1 only minimally involved in complement-related mechanisms123. In contrast, IgG2b antibodies would 
be able to support both mechanisms, being not as efficient as IgG1 in T cell reactivation, but maybe having a 
more important role in complement-dependent CNS demyelination.  
Effector T cells produce cytokines upon activation that trigger the recruitment of other immune cells, 
promoting disease development87. Previously, it was reported that the disease acceleration effect was 
accompanied by an enhanced cytokine production in the CNS of animals administered with IgG1 
autoantibodies87. This raised the question whether the enhanced cytokine production was a consequence of 
higher numbers of activated T cells infiltrating the CNS, or rather due to higher cytokine expression levels of 
individual activated T cells upon administration of MOG isotypes. Our results showed that, although sorted 
GFP positive T cells produced higher amounts of pro-inflammatory cytokines compared to non-activated 
sorted GFP negative T cells, similar amounts of cytokine transcripts were found in GFP+ activated T cells among 
all the different antibody isotypes and their respective isotype controls (Figure 19). These results indicate that 
enhanced cytokine production of individual cells upon administration of different antibody isotypes is not 
crucial for disease acceleration, but rather the enhanced numbers of CD4+ T cells reactivated within the CNS. 
However, the Nur77 GFP reporter might not be a suitable system with which evaluate the peak of cytokine 
production, since this has been reported to be measurable 30 min after stimulation of human CD4+ and CD8+ 
T cells, peaking at 3-4 hours post stimulation124,125,126. In contrast, detection of GFP in activated Nur77 GFP T 
cells is possible after two hours and has its maximum emission 12 to 24 hours after antigen stimulation in 
vitro101. Therefore, it is possible that the peak of GFP expression and cytokine production are not synchronised, 
preventing us from detecting differences upon administration of different antibody isotypes.  
8.18c5 IgE, and Z2 IgE and IgA did not have an effect in disease acceleration (Figure 16, 17 and 21). 
Furthermore, increased numbers of activated T cells were not observed when 8.18c5 IgE was administered 
(Figure 19). Although further experiments are required in order to confirm these results, it seems that IgE and 
IgA isotypes cannot accelerate disease onset and aggravate EAE. The absence of the aforementioned effects 
upon administration of these antibody isotypes could be due to their particular structural and functional 
properties.  
Regarding IgE, murine half-life of IgE is short in comparison to other antibody isotypes62, which may explain 
the absence of pathogenic effects. Several mechanisms have been proposed to explain the short half-life of 
IgE, such as a higher sensitivity of IgE for proteases or competition with IgGs for binding available FcRn 
molecules at the endosomal compartments127. In order to substantiate that the absence of disease 
acceleration upon administration of IgE was related to the isotype and not to its short half-life, we 
administered IgE on three consecutive days. However, triple administration of IgE was not sufficient to trigger 
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disease acceleration, nor was administration of higher doses of IgE, independently of the administration route 
(Figure 17, 21 and 22). Furthermore, while fluorescently labelled 8.18c5 IgG1 has been shown to be present 
within the CNS 4-5 days after administration87, there is no available data regarding the arrival of MOG-specific 
IgE to the CNS, and therefore 2-photon experiments using labelled IgE antibodies are necessary to investigate 
the role of this isotype in EAE.  
IgE triggers its effector mechanisms through binding to the FcεRI, which is expressed by basophils and mast 
cells, and FcεRII, which is expressed by T and B cells as well as different myeloid cell populations128,129. 
Crosslinking of the FcεRI lead to degranulation of basophils and mast cells, and activation of FcεRII leads to 
suppression of IgE production by B cells, but it also may be involved in antigen presentation to allergen specific 
T cells130. Since we did not observe disease acceleration upon administration of IgE, the potential role of FcεRII 
in our disease model might be not crucial for disease exacerbation. However, IgE might exert disease-
modifying effects through mast cell and basophils degranulation in EAE. Mast cells are known to regulate 
vascular permeability, and they are found in close relationship with BBB vasculature and with nerves131. Mast 
cells can not only be found in the non-inflammed CNS tissue, such as in the thalamus and hippocampus, but 
they have also been found in demyelinating lesions of MS patients, and also as transcripts of tryptase, which 
can promote demyelination131,132. Some authors have claimed a pathogenic role for mast cells using mast cell-
deficient mice (c-kit KO), since these animals had an ameliorated disease progression133,134. In these studies, 
bone marrow mononuclear cell transplantation reconstituted mast cell populations and rescued EAE severity. 
However, c-kit deficiency affects mast cells but also induce several defects including lymphocyte development, 
indicating that this model might not be a suitable one for studying mast cell biology. Other authors recently 
tried to address the role of mast cells in EAE in a more direct way using KO animals for carboxypeptidase A 
and for c-kit. Their results showed that both KO models are equally susceptible to MOG-induced EAE, 
presenting similar clinical outcome and histpathological profiles and, consequently, suggesting a minor role 
for mast cells in the EAE model135. However, recent publications indicated a protective role of mast cells and 
basophils in EAE, since treatment with anti-FcεRI antibodies enhanced EAE severity through a polarization of 
the immune response towards a Th1 and Th17 phenotype136. Future experiments in our model using the knock 
out mice for the Fc common-γ chain, which is also part of the FcεRI96, are required to further study the role of 
IgE in autoimmunity.  
In contrast to humans, IgA is together with IgE the least abundant antibody isotype found in young and adult 
mice50, and it also has a short half-life62. Since we did not observe disease-modifying effects upon 
administration of IgA (Figure 21), it is possible that this antibody isotype does not reach the CNS in enough 
quantities in order to exert these effects. Therefore, 2-photon in vivo studies using labelled IgA are required 
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to test whether this isotype is able to reach the CNS, as well as administration of this isotype on consecutive 
time points.  
IgA is known to play an important role in gut homeostasis through its binding to the pIgR and the Fcα/µR. 
While pIgR mediate the transport across the epithelium of sIgA in the gut, Fcα/µR is internalized upon 
crosslinking with IgM and IgA on B cells and macrophages, and it presumably participates in antigen 
presentation137. Intestinal IgA-producing plasma cells have been recently reported to dampen EAE 
neuroinflammation through the production of IL-10, having therefore an anti-inflammatory effect in the CNS. 
However, these studies did not find significant evidence of IgA antibody-driven disease modulatory effects 
since irradiated B cell deficient animals (Jht -/-) reconstituted either with IgA-deficient BM or WT BM developed 
a similar EAE severity138. The presence of IgA autoantibodies against native myelin basic protein in the CNS has 
been recently reported in MS patients139, and the role of the gut microbiome within MS pathology is 
progressively gaining attention140. Alterations in the gut microbiome lead to different outcomes in the EAE 
model. For example, mice kept in germ-free conditions present a decreased EAE incidence, fewer Peyer´s 
patches and reduced production of IgA140,141. In this line, antibiotic treatment with kanamycin, colistin and 
vancomycin one week before immunization reduced EAE severity, together with a decrease of IFNγ, TNFα, IL-
6 and IL-17 production140. Additionally, B-cell development, activation and differentiation have been shown to 
be influenced by microbial products and gut microbiota, since stimulation of Toll-like receptors in the intestinal 
lumen trigger the release of BAFF and APRIL, leading to B cell activation and promoting CSR towards IgA-
producing plasma cells142,143. Finally, IgA deficiency is the most common immunoglobulin deficiency in humans, 
which shows variances between different geographical regions, but it is also associated with autoimmunity144. 
Taking all these factors into consideration, further experiments are required to understand the role of IgA in 
our model. 
The initial reports that pointed towards the role of B cells in EAE made also reference to the participation of 
IgM antibodies in this model. Rats administered with anti-IgM antibodies failed to develop EAE when they 
were administered with guinea pig spinal cord homogenate or purified MBP145. This EAE resistance was 
counteracted upon administration of serum containing anti-MBP into anti-IgM treated animals, indicating that 
although IgM is not required in order to generate autoreactive effector T cells, this isotype facilitates the 
development of the disease146. On the other hand, IgM-dependent protection against autoimmunity has been 
also suggested, since patients with selective IgM deficiency are more prone to develop other autoimmune 
diseases147,148. Furthermore, FcμR KO animals produce less antibodies in primary and memory immune 
responses and, as they become older, they produce more autoantibodies than control animals149. However, 
in our experimental setup, antibodies are administered briefly before disease onset, and therefore it is not 
likely that the reported tolerance induction mechanisms of IgM could take place. Although IgM present a half-
72 
 
life of two days in adult mice62, 2-Photon in vivo experiments using labelled IgM would also be required in 
order to test whether this isotype can reach the CNS, since given its high molecular weight, it is possible that 
IgM cannot cross the blood-brain barrier even when disrupted.  
In this study, we additionally sought to address the question of whether Fcγ receptors play a role in 
autoantibody-dependent disease acceleration in EAE. Our experiments revealed that elimination of the FcRn, 
Fcγ type I activating receptors I and III, and the common-γ chain plus Fc receptor IIB, did not modify the 
performance of 8.18c5 IgG1 regarding disease acceleration. However, this effect was abrogated in FcγRI-IV KO 
animals in an isotype-independent manner (Figure 24 and 25), suggesting that the expression of FcγRs is 
crucial for an earlier disease manifestation.  
FcRn plays important roles extending the half-life of immunoglobulins, specifically that of IgGs, since they are 
the most common antibodies found in serum and presumably they occupy the majority of FcRn units 
available113,127. Furthermore, the FcRn has been implicated in antigen processing by dendritic cells when upon 
uptake of immune complexes, avoiding their degradation in the lysosome compartment63. This is probably not 
the case in our experimental setup, since elimination of the FcRn was not sufficient to abrogate IgG1-driven 
disease acceleration effects (Figure 24). These results indicate that the effector mechanisms of IgG1 are 
triggered in a relatively short timeframe, which does not necessarily require the interaction with FcRn. An 
interesting follow-up experiment is the evaluation of T cell activation in FcRn KO mice upon adoptive transfer 
of cells from Nur77-GFP animals, since it is possible that upon administration of IgG1 antibodies similar 
amounts of activated T cells could be found in the CNS of these animals, even when the half-life of this 
immunoglobulin is compromised.  
Regarding the KO animals for the FcyRI and III, other studies found EAE disease amelioration upon knock out 
of FcγRIII150, and no effects compared to WT upon ablation of FcγRI151. In line with these latter studies, we did 
not find an abrogation of EAE disease acceleration (Figure 24). Based on recent results from our department, 
it seems that compensatory mechanisms concerning the expression among the different FcγRs could explain 
the continuation of the antibody-driven disease acceleration effect109.  
The common-γ chain FcγR KO model has been the most frequently used FcR KO model in the previous years, 
although conflictive results concerning the role of activating FcγRs in EAE susceptibility have been published 
using this model88,152. In these animals, expression of the activating FcγRs alpha chains is compromised but not 
completely abrogated96, which could be sufficient to mediate internalization and processing of immune 
complexes, leading to disease acceleration in our model. In fact, our experiments using common-γ chain FcγR 
KO animals and carrying additionally a KO for the FcγR IIB showed that knock out of these elements is not 
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sufficient to abrogate the acceleration effect (Figure 24). Therefore, we could support other results which also 
found disease acceleration effects upon administration of 8.18c5 in this KO model96. 
In summary, our results indicate that the disease acceleration effect in the EAE model is isotype dependent, 
where IgGs play a crucial role, and it requires necessarily the expression of FcγRs in order to be triggered. 
Regarding the other antibody-effector mechanism tested in this study, namely CNS demyelination, 
autoantibodies can target a cytotoxic attack to myelin structures through ADCC or activation of the 
complement cascade, leading to enhanced demyelination and tissue destruction38,84. Previous results from our 
department showed that animals administered with low doses of 8.18c5 IgG1 did not show enhanced 
demyelination briefly after disease onset, although the disease acceleration effect was still present87. However, 
several studies reported a high demyelinating potential of MOG-specific autoantibodies38,153, as well as upon 
administration of 150 µl of serum from Th mice at later disease stages in 2D2 animals86. In comparison to these 
studies, our model is characterized by the administration of low quantities of autoantibodies. Therefore, we 
sought to address whether CNS demyelination could be affected by increasing doses of autoantibodies at the 
peak of the disease, as well as the role of different antibody isotypes targeting MOG regarding CNS 
demyelination.  
We could show that low doses of 8.18c5 IgG1 did not enhanced demyelination, but in line with previous studies, 
higher doses of this antibody isotype led to enhanced demyelination of the spinal cord (Figure 20, 22 and 
Table 5). Irrespectively of the dose applied, all animals treated with 8.18c5 IgG1 presented an accelerated 
disease onset, suggesting that demyelination and disease acceleration are two independent mechanisms of 
autoantibodies. Furthermore, antibody-dependent demyelination seems not only to be modulated by the 
concentration of the antibody, but also by the isotype (Figure 20, 22 and Table 5). In this regard, CNS damage 
was more pronounced upon administration of 8.18c5 IgG2b and Z2 IgG2a, while 8.18c5 IgE, Z2 IgE, and Z2 IgA 
did not have an effect on spinal cord demyelination. Intrathecal administration of different antibody isotypes 
showed similar results (Figure 22), but only in case the antibodies were administered at early time points 
rather than at the peak of the disease (Figure 23). Taken together, these data indicate that IgGs are the only 
antibody isotypes with the capacity to trigger an enhancement of CNS demyelination but with differential 
outcome between the IgG subclasses. 
It seems that the threshold required for IgG1 in order to exert disease acceleration and CNS demyelination is 
different, being more efficient in accelerating EAE onset than triggering demyelination and CNS damage 
through ADCC and CDC. This could be a consequence of IgG1 molecular properties, since IgG1 antibodies are 
more efficient in binding to FcγRs than in complement fixation compared to other antibody isotypes122,64. 
Supporting this idea, previous studies suggested that the demyelinating potential of MOG autoantibodies is 
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based on their ability to fix complement153, being Z2 IgG2a antibodies more efficient triggering SC 
demyelination than 8.18c5 IgG1. In line with this, it is known that complement fixation is isotype-dependent, 
given that IgG2a and IgG2b are more efficient in this process than IgG1 antibodies64. Therefore, complement 
fixation seems to be a good candidate to investigate the exact mechanism of isotype-dependent 
demyelination in our model. 
Increasing doses of IgE and IgA did not lead to enhanced demyelination, as well as direct administration of 
8.18c5 IgE into the CNS (Figure 20, 22 and Table 5). Since CDCC and CDC are most likely driving CNS 
demyelination in our model84, it is not surprising that we did not observed IgE-mediated demyelinating effects, 
as this antibody is reported not to be able to fix complement154. However, infiltrating cells expressing non-
occupied FcεRI molecules in their surface could recognize immune complexes containing myelin debris and 
IgE, and release pro-inflammatory cytokines and proteases which can exert further damage within the CNS 
tissue through ADCC155,156. This seems not to be the case, since FcεRIs non-occupied by IgE have a half-life of 
24 hours in vitro, therefore the binding of IgE to this receptor is necessary in order to avoid the recycling of 
the receptor68,157. In vivo 2-Photon studies and FACs analyses tracking labelled IgE are required to substantiate 
our evidence of a lack of effect on demyelination of this antibody isotype seen so far in our model. On the 
other hand, IgA does not trigger the activation of the classical complement pathway, but it is known to activate 
the alternative complement pathway and the mannose lectin complement pathway73-74, which also have been 
reported to play a role in the EAE model158. Given the short half-life of IgA, it is possible that larger amounts 
are required to trigger its demyelinating potential. Furthermore, in this study we did not test the effect of 
direct administration of IgA into the CNS, which could lead to enhanced demyelination by CDCC or CDC.  
Taking the potential role of complement in our model into consideration, the generation of MOG-specific IgM 
and IgG3 in the 8.18c5 and Z2 hybridoma cell lines would be particularly interesting. These two antibody 
isotypes possess a particular immunostimulatory capacity including a positive feedback loop for antibody 
responses, which seems to be complement-dependent123,159. In this line, both antibodies are known to 
efficiently bind to complement123,160,161, and IgG3 can oligomerize recruiting more easily C1q subunits162. 
Consequently, in our model these antibody isotypes could significantly boost spinal cord demyelination 
through CDCC and CDC, and perhaps by the establishment of a positive feedback loop of antibody production. 
Concerning the function of IgM and IgG3 in a different context, in other EAE models using rhesus, marmoset 
and cynomolgus monkeys, EAE development was correlated with high anti-rhMOG IgM responses, indicating 
that the IgM-driven humoral response is essential in these models for disease induction. Finally, in MS patients 
it is described that intrathecal IgM production correlates with a severe disease course, leading to the 
appearance of more spinal cord lesions163.  
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Variations in CNS demyelination was not accompanied by further infiltrating T cells (Figure 20), but upon 
higher doses of IgG2b and IgG2a, increased numbers of cells positive for MAC3 were present, indicating that 
these antibody isotypes can induce the recruitment of macrophages to the CNS, or activate microglial cells 
more efficiently. Characterization by qRT-PCR of cytokines such as TNFα, IL-1β, IL-6, and macrophage-
recruiting chemokines such as CXCR5 and CCR5, in total CNS tissue, as well as per cell analyses of infiltrating 
macrophages and microglia cells, could help us to understand the role of IgG2b and IgG2a in macrophage 
recruitment. Finally, since histological approaches are conditioned by the analysed sections, which do not 
necessarily always reflect the infiltration status of the tissue, evaluation of macrophage infiltration should be 
further characterized by FACs staining of CD11b+ CD45+ populations to be able to get a better overview of the 
infiltration of myeloid cells.   
The role of Fcγ receptors in autoantibody-dependent demyelination was also addressed in this study. Our 
experiments revealed that elimination of the FcRn, Fcγ type I activating receptors I and III, and the common-γ 
chain plus Fcγ receptor IIB, did not modify the performance of 8.18c5 IgG1 in SC demyelination (Figure 24). 
However, FcγRI-IV KO animals showed enhanced demyelination compared to WT animals when administered 
with isotype control, as well as enhanced demyelination upon administration of 50 µg of 8.18c5 compared to 
FcγRI-IV treated with isotype control (Figure 24). Enhancement of demyelination in FcγRI-IV KO animals was 
also isotype dependent, since both IgG1 and IgG2b exerted higher demyelination than IgE (Figure 25), 
recreating a similar situation to the one observed in WT animals. Interestingly, in this setup both 50 µg of IgG1 
and IgG2b exerted comparable CNS demyelination, suggesting that a maximum demyelination plateau can be 
reached in our model with no further possible exacerbation. Whether other antibody isotypes perform 
differently in FcγRs I-IV KO animals needs to be addressed using further antibody isotypes derived from the 
8.18c5 and Z2 hybridoma cell lines. 
Our data suggest that antibody-dependent disease acceleration and demyelination seem to be independent 
mechanisms. However, our experiments using the FcγRI-IV KO model suggest that these two mechanisms are 
closely interrelated. The abrogation of the disease acceleration effect and at the same time the enhanced 
demyelination observed in FcγRI-IV KO animals could indicate that, since antibodies cannot bind to these 
receptors anymore, the uptake of immune complexes by APCs would be limited. Thereby, a more efficient 
reactivation of T cells would no longer be possible, leading to an abrogation of the disease accelerating effect. 
However, these antibodies would now preferentially bind to myelin and therefore could promote CNS 
demyelination through the only available system, the complement cascade, which has been extensively 
implicated in myelin destruction in the EAE model164. This could also imply that the threshold required for a 
particular isotype to fix complement would be more easily reached, which is supported by the enhanced 
demyelination found in FcγRI-IV KO animals treated with isotype control. Our immunization protocol using 
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MOG35-55 peptide results in the production of very low endogenous MOG-autoantibody titers85. Consequently, 
in case that the FcγRs are not present, the threshold for antibodies to fix complement would be lowered and 
a small titer of antibodies upon immunization would be sufficient to promote CNS demyelination through 
CDCC or CDC. Murine IgG1 represents a good example for this interpretation, since it is known that this 
antibody isotype is more efficient binding to its FcγRs than fixing complement89,123,165. However, low amounts 
of this antibody isotype enhanced dramatically CNS demyelination when FcγRs expression was abrogated, 
indicating that the threshold for this isotype to trigger myelin damage is lowered in this context. 
Furthermore, in the EAE model a crucial role has been shown for complement in autoantibody-mediated 
demyelination which seems to be independent of activating Fcγ-receptors164. This study showed that KO 
animals for the complement subunit C1q, which triggers the activation of the classical complement pathway, 
did not show enhanced demyelination upon administration of 8.18c5, while WT animals and FcR common-γ 
chain KO animals did. In addition, amelioration of other autoimmune diseases has been reported upon specific 
block of the different complement pathways90. Consequently, it is likely that the potential effector 
mechanisms implicated in CNS demyelination in the EAE model are CDCC and CDC, where the complement 
cascade would be triggered upon binding of autoantibodies to MOG. In our model, complete inhibition of the 
complement cascade could abrogate the IgG2b- and IgG2a-driven enhancement of demyelination, while IgG-
dependent disease acceleration could still be present or slightly ameliorated. Nevertheless, further 
experiments using KO animals for the complement subunit C1q, as well as pharmacological approaches using 
inhibitors for the different complement pathways are required to clarify the importance of the isotype in 
complement-mediated demyelination.  
Further antibody molecular properties such as glycosylation influence antibody effector mechanisms114. 
Although a difference in the clinical outcome of EAE was not observed upon administration of deglycosylated 
8.18c5 and isotype control in our experiments (Figure 26), further experiments are necessary to confirm these 
results. Moreover, since EAE clinics do not necessarily correlate with histopathological marks such as spinal 
cord demyelination87,3, further studies are required to confirm the effect of complete deglycosylation in our 
EAE model. Additionally, removal of specific residues at the antibody Asn 297 glycosylation site has been 
reported to modify the outcome of the immune response166,167. For example, while sialylation removal 
promote anti-inflammatory responses, ADCC is boosted by removal of fucose. Therefore, our observations 
concerning antibody effector mechanisms such as disease acceleration or demyelination could be influenced 
by alterations in antibody glycosylation patterns. 
In a previous report84, it was shown that the antibodies derived from the hybridoma cell lines 8.18c5 and Z2 
exert different effector functions and differ in their demyelinating capacity. On the other hand, these 
antibodies are of a different isotype, but they also do not exactly bind to the same epitope at the FG loop of 
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MOG104,105. Therefore, it remained unclear whether the difference in effector function is due to the isotype or 
to the epitope specificity. With our approach, it is in principle possible to clarify this issue. In this study, the 
role of MOG-specific IgE antibodies derived from both hybridoma cell lines was addressed. In both cases, 
antibodies of the IgE isotype were not able to exert disease-modifying effects, either in the active EAE model 
or in the transfer EAE model. Unfortunately, antibodies of exactly the same isotype with the 8.18c5 and Z2 
specificity could not be directly compared, but 8.18c5 IgG2b and Z2 IgG2a showed striking similarities both in 
respect to disease acceleration and demyelination. It therefore seems that the isotype rather than fine epitope 
specificity is crucial for the prediction of the effector mechanisms preferentially used by MOG-specific 
antibodies. Production of the remaining antibody isotypes from both hybridoma cell lines, and further 
experiments comparing systematically these isotypes, is required in order to finally address this question. 
8.18c5 Fab fragments could not exert disease-modifying effects, and failed to accelerate the disease, 
underscoring that the relevant effector mechanisms are strictly dependent on the Fc portion of the antibodies 
and that the effects were not due to simple binding of the antibodies to their cognate antigen109. In addition, 
several publications reported previously that the specificity of antibodies can be modified upon CSR168,169. This 
would provide a scenario were CSR could induce fine modifications at the antigen binding site, making 
antibodies more efficient recognizing their targets and helping to explain the preference for the production of 
certain isotypes within concrete immune responses (such as viruses or helmints). This is probably not the case 
in our model, since our CRISPR-Cas9 based system is most likely not triggering the natural CSR process, but 
rather inducing a DNA DSB which functional consequence is uniquely a switch of the isotype.  
Finally, ADCC and CDC are important FcR-mediated mechanisms in our model170,28. Antibodies binding directly 
to myelin could be recognized by macrophages, neutrophils and other Fc receptor expressing cells66, targeting 
myelin destruction. Generation of antibodies derived from the 8.18c5 and Z2 hybridoma cell lines carrying 
mutations at the CH2-CH3 region (where the Fc receptor binding site is located) will provide us a useful tool 
with which to further investigate the triggering of ADCC in our model171,172. Regarding CDCC and CDC, 
mutations at the complement binding site in the 8.18c5 and Z2 hybridoma cell lines will give us insights into 
the role of complement in our model89,173, since a relationship between complement and demyelinating 
antibodies concerning demyelination as an effector mechanism has been previously reported84. These studies 
showed that Z2 IgG2a antibodies are more efficiently fixing complement and demyelinating rat CNS tissue 
than 8.18c5 IgG1 antibodies, which goes in line with the literature regarding isotype-dependent complement 
fixation capacity, since IgM, IgG3, IgG2a and IgG2b are known to fix complement more efficiently than IgG1, 
IgA and IgE in mice122,165,162. Therefore, production of these additional tools would help us to understand the 
relationship between FcR-mediated mechanisms and complement-dependent mechanisms in our model. 
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In summary, antibodies exert different pathogenic mechanisms depending on their molecular properties in 
the EAE model, with the isotype being the main variable preferentially investigated is this study. Based on 
their affinity to FcRs and their ability to fix complement, antibody isotypes exert their effector mechanisms 
preferentially through one of these two systems, which can be balanced towards one or the other when some 
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